finance report finance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sale chf chf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december definition cer core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset allow assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business free cash flow concept fully describe page reconciliation ifrs cash flow free cash flow give therefinance report roche group finance brief roche roche group report good overall result sale grow constant exchange rate cer ifrs net income decrease cer core earning share increase cer appreciation swiss franc adverse impact result express swiss franc sale group sale increase cer chf billion increase chf term pharmaceutical sale increase cer drive grow demand new medicine include ocrevus hemlibra vabysmo evrysdi tecentriq diagnostic sale show growth cer growth routine testing compensate low sale covidrelate product operating result core operating profit increase cer chf billion increase chf term research development expenditure grow cer chf billion core basis oncology remain primary area cancer immunotherapy portfolio key driver neuroscience immunology ophthalmology represent significant area spend pharmaceutical division research development cost represent group sale ifrs operating result low cer include noncore expense chf billion intangible asset impairment charge pharmaceutical division nonoperate result finance cost ifrs increase cer chf billion issuance debt december february march september increase interest rate income tax expense ifrs increased cer chf billion effective core tax rate increase mainly impact resolution tax dispute reduce group effective core tax rate percentage point compare percentage point net income ifrs net income chf billion decrease cer decrease chf term decrease high impairment intangible asset high interest cost income taxis core earning share increase cer chf chf term repurchase share novartis consequent additional financing cost accretive effect net tax approximately percentage point ifrs ep approximately percentage point core ep cash flow operate free cash flow remain strong chf billion decrease cer decrease chf term increase net work capital free cash flow decrease cer decrease chf term chf billion drive low operate free cash flow high tax payment financial position net work capital increase drive high trade receivables pharmaceutical division high inventory division net debt decrease chf billion chf billion free cash flow exceed dividend payment credit rating remain strong aa standard poor aa moodys aa fitch shareholder return proposal increase dividend chf share nonvoting equity security represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr minus represent combine performance share nonvoting equity security development roche share price influence negative news flow research development pipeline expect decline covidrelated sale roche group finance report roche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle current liability operating segment information provision contingent liability revenue debt net financial expense equity attributable roche shareholder income taxis subsidiary associate merger acquisition noncontrolle interest global restructuring plan employee benefit property plant equipment pension postemployment goodwill benefit intangible asset equity compensation plan inventory lease account receivable earning share nonvoting marketable security equity security cash cash equivalent statement cash flow noncurrent asset risk management current asset relate party account payable list subsidiary associate noncurrent liabilitie significant accounting policy report roche management internal control financial report statutory auditor report general meeting roche holding ltd basel multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement appropriation available earning statutory auditor report general meeting roche holding ltd basel finance report financial review roche group financial review roche group result finance brief inside cover sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group achieve sale growth constant exchange rate cer core operate profit growth ifrs net income decrease cer core eps increase cer adverse impact result express swiss franc compare constant exchange rate percentage point sale percentage point core operating profit percentage point ifrs net income core eps pharmaceutical division sale higher continue uptake new medicine despite negative impact biosimilar competition low sale actemraroactemra covid diagnostic division growth routine testing compensate drop demand covidrelated product core operate profit growth reflect sale growth income ultomiris patent settlement offset lower ronapreve profitshare income regeneron ifrs net income decrease core ep increase ifrs net income include impairment intangible asset chf billion drive reduce sale expectation late research datum core eps increase include positive impact approximately percentage point share repurchase novartis net additional financing cost tax ultomiris patent settlement positive impact approximately percentage point core ep lower ronapreve profitshare income negative impact approximately percentage point core eps net tax operate free cash flow remain strong chf billion decrease increase net work capital free cash flow chf billion decrease result low operating free cash flow high tax payment roche group financial review finance report divisional operating result pharmaceutical diagnostic corporate group chf chf chf chf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale change cer core operating profit change cer margin percentage point change operate profit change cer margin percentage point change operate free cash flow change cer margin percentage point change sale pharmaceutical division chf billion chf billion increase cer drive grow demand ocrevus hemlibra vabysmo evrysdi tecentriq contribute additional chf billion cer sale sale mabtherarituxan herceptin avastin decrease combine chf billion cer impact biosimilar competition continue low rate previous year covidrelated sale decline sale actemraroactemra lower ronapreve high sale japan compensate low sale europe diagnostic division report sale chf billion increase cer sale growth drive increase routine testing region partly offset low sale covidrelate product sale division base business increase cer immunodiagnostic business main growth driver total sale covid relate test notably sarscov rapid antigen tests cer low chf billion chf billion pharmaceutical division core operating profit increase cer sale increase chf billion income ultomiris patent settlement largely offset reduction chf billion ronapreve profitshare income regeneron cost sale decrease mainly low manufacturing cost drive high cost response covid pandemic favourable product mix impact marketing distribution cost increase drive high spending digital customer solution launch prelaunch activity research development cost chf billion oncology remain primary area cancer immunotherapy portfolio key driver neuroscience immunology ophthalmology represent significant area spend increase research development cost drive investment gene therapy chugai early research developmentfinance report financial review roche group diagnostic division core operating profit decrease cer chf billion despite sale growth cost sale increase ahead sale growth unfavourable product mix impact covid relate test high cost freight marketing distribution expense increase cer result high distribution cost relate sarscov rapid antigen test partly offset low personnel expense research development cost increase digital solution main growth driver addition investment continue project sequence cardiac disease mass spectrometry ifrs operating profit decrease cer pharmaceutical division contrast growth core operating profit high intangible asset impairment diagnostic division ifrs operating profit increase cer base effect significant spending restructuring activity result group include chf billion impairment intangible asset chf billion intangible asset amortisation chf billion expense global restructuring plan finance core cost increase cer chf billion additional interest expense new debt issue finance share repurchase novartis increase interest rate affect shortterm borrowing cost financial income expense contribute chf billion core basis high net foreign exchange loss high loss net monetary position hyperinflationary economy argentina trkiye group effective core tax rate increase compare increase mainly impact resolution tax dispute reduce group effective core tax rate percentage point compare percentage point net income decrease cer ifrs basis chf billion decrease cer core basis chf billion net income attributable noncontrolle interest increase ifrs basis core basis impact ultomiris patent settlement chugai operate free cash flow chf billion decrease cer increase net work capital free cash flow chf billion decrease cer result lower operating free cash flow high tax payment roche group financial review finance report income statement change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf page definition core result core epsfinance report financial review roche group impact covid pandemic pharmaceutical division actemraroactemra receive fda approval treatment covid hospitalise adult retain emergency use authorization child age sale chf billion decline cer low demand patient sale ronapreve neutralise antibody combination develop regeneron chf billion high sale japan offset low sale europe decline chf billion profitshare income regeneron relate sale ronapreve diagnostic division portfolio covid test notably sarscov rapid antigen test generate sale chf billion chf billion decline cer low demand covidrelated product competition biosimilar generic medicine group pharmaceutical product generally protect patent right intend provide group exclusive marketing right country patent right vary scope duration group required enter costly litigation enforce patent intellectual property right loss market exclusivity major product patent expiration challenge generic medicine biosimilar non comparable biologic reason material adverse effect group business result operation financial condition introduction generic biosimilar noncomparable biologic version similar medicine usually result significant reduction net sale relevant product manufacturer typically offer version low price patent expiry integral group business model future growth remain driven innovation late information clinical study include annual report detail group product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm mabtherarituxan herceptin avastin group basic primary patent product expire worldwide inlicense halozyme patent right subcutaneous formulation mabtherarituxan herceptin begin expire sale include regional breakdown mabtherarituxan herceptin avastin disclose pharmaceutical division operating result summarise table yearonyear movement drive regular price volume change biosimilar competition factor overall picture total mabtherarituxan herceptin avastin sale change divisional sale divisional sale chf chf cer united states europe japan international total sale biosimilar version herceptin avastin launch mid biosimilar version mabtherarituxan late europe biosimilar version mabtherarituxan herceptin launch mid mid respectively market eu country biosimilar version avastin come market europe mid biosimilar version mabtherarituxan herceptin launch japan biosimilar version avastin launch late colorectal cancer indication nonsmall cell lung cancer indication breast cancer indication sale product japan impact government price cut biosimilar competition international region biosimilar version product launch country impact regular price volume change lead decline sale lucentis group basic primary patent expire biosimilar version lucentis restrict label come market begin quarter sale lucentis chf million chf million decline cer report dollar competitive pressure esbriet follow negative decision district court district delaware march generic version esbriet came market second quarter sale esbriet chf million chf million decline cer report dollar roche group financial review finance report actemraroactemra group basic primary patent expire eu base publicly available information competitor company group currently anticipate biosimilar version actemraroactemra come market eu second half global sale actemraroactemra chf million chf million decline cer drive low demand hospitalise patient covid merger acquisition asset acquisition september group acquire control interest good therapeutics inc good therapeutic privately own company base seattle washington acquisition group gain access good therapeutic pdregulate il programme good therapeutic report pharmaceutical division cash consideration pay acquisition date usd billion additional contingent payment base achievement performancerelate milestone transaction qualify business combination ifrs account addition intangible asset detail give note annual financial statement alliance transaction inlicense alliance transaction result intangible asset chf billion chf billion recognise global restructuring plan pharmaceutical division initiate portfolio prioritisation programme group continue implementation global restructuring plan initiate prior year global restructuring plan cost incur millions chf global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost business process transformation simplify system landscape streamline process complexity incur employeerelate cost chf million chf million reorganisation expense chf million chf million transformation multiyear crossdivisional programme drive efficiency gain manufacturing network strategy review pharmaceutical division incur site closure cost chf million chf million relate site switzerland germany additionally pharmaceutical division portfolio prioritisation programme incur cost chf million mainly relate closure study major item global restructuring cost employeerelate cost business transformation initiative pharmaceutical division strategy plan diagnostic division notably diabete care site development baselkaiseraugst site switzerland detail give note annual financial statementsfinance report financial review roche group impairment goodwill intangible asset pharmaceutical division pharmaceutical division record impairment charge intangible asset chf billion drive reduce sale expectation late research datum major item charge chf billion impairment inlicense gavreto intangible asset charge chf billion partial impairment intangible asset spk novel gene therapy treatment haemophilia acquire spark therapeutic acquisition impairment charge chf billion prm novel antifibrotic immunomodulator treatment idiopathic pulmonary fibrosis acquire promedior acquisition chf billion flatiron technology chf billion rozlytrek acquire ignyta acquisition diagnostic division impairment goodwill intangible asset impairment charge chf billion pharmaceutical division diagnostic division detail give note annual financial statement legal environmental case significant development detail give note annual financial statement share repurchase december roche group repurchase million roche share hold novartis total consideration chf billion repurchased share report treasury share december cancellation share february share capital roche holding ltd group parent company decrease chf million chf million chf million chf billion bridge loan facility draw finance share repurchase fully repay partly proceed new debt issuance partly internal cash generation detail give note annual financial statement net income earning share ifrs net income decrease core eps increase repurchase share novartis consequent additional financing cost accretive effect net tax approximately percentage point ifrs eps approximately percentage point core eps ultomiris patent settlement accretive impact net tax approximately percentage point core ep reduction ronapreve profitshare income dilutive impact net tax approximately percentage point core ep core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset merger acquisition alliance transaction net income attributable noncontrolle interest increase ifrs basis core basis impact ultomiris patent settlement chugai net income change change chf chf chf cer ifrs net income reconcile item net tax global restructuring plan intangible asset amortisation goodwill intangible asset impairment merger acquisition alliance transaction legal environmental case normalisation equity compensation plan tax benefit core net income supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result roche group financial review finance report financial position financial position change change chf chf chf cer pharmaceutical net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operate asset net debt lease liability pension income taxis nonoperate asset net total net asset compare start year swiss franc appreciate significantly japanese yen euro negative translation effect group net operating asset exchange rate give net work capital increase division pharmaceutical division net working capital high cer mainly increase trade receivables drive ronapreve sale japan december increase inventory ensure supply resilience notably actemraroactemra rampup launch product vabysmo phesgo main driver diagnostic division net work capital high cer drive high inventory increase support growth division base business increase inbound shipment instrument end year decrease net debt free cash flow chf billion partly offset dividend payment chf billion chf billion bridge loan facility draw finance share repurchase novartis fully repay partly proceed new debt issuance partly internal cash generation lease liability decrease chf billion regular payment net pension liability low cer follow increase discount rate net asset position income taxis increase mainly taxis pay exceed income tax expense partially offset defer tax effect pension equity compensation plan free cash flow free cash flow change change chf chf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay free cash flow page definition free cash flow detailed breakdown group operate free cash flow chf billion decrease cer increase net work capital particular trade receivables pharmaceutical division inventory division free cash flow chf billion decrease cer result lower operating free cash flow high shortterm borrowing cost increase interest rate high tax payment notably japanfinance report financial review roche group pharmaceutical division operating result pharmaceutical division operating result change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operating income revenue cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow b operate free cash flow margin sale page definition core result b page definition free cash flow sale overview pharmaceutical division sale therapeutic area change sale sale chf chf cer oncology neuroscience immunology haemophilia infectious disease ophthalmology therapeutic area total sale roche group financial review finance report sale pharmaceutical division chf billion chf billion increase cer continue grow demand ocrevus hemlibra vabysmo evrysdi tecentriq contribute additional chf billion cer sale demand ocrevus remain strong indication sale increase chf billion hemlibra continue significant uptake sale reach chf billion increase vabysmo approve january show high initial uptake sale chf billion evrysdi sale continue strong uptake region drive europe international region sale growth tecentriq sale grow chf billion drive europe sale oncology therapeutic area decrease cer biosimilar competition mabtherarituxan herceptin avastin partially compensate growth tecentriq phesgo polivy alecensa perjeta kadcyla tecentriq sale grow high demand france phesgo continue considerable uptake predominantly europe total sale chf billion sale alecensa grow region china main driver kadcyla show growth primarily international region follow europe sale growth drive usage kadcyla early breast cancer set perjeta sale grow notably international region high demand china early metastatic breast cancer setting partly offset decline perjeta sale europe follow launch phesgo sale neuroscience grow cer mainly ocrevus evrysdi growth driver sale chf billion follow high uptake europe international region sale immunology decrease follow decrease actemraroactemra sale low demand hospitalise patient covid sale esbriet low result generic competition decline immunology sale partly offset high sale xolair drive steady growth chronic spontaneous urticaria indication infectious disease therapeutic area sale ronapreve increase high sale japan sale rocephin decline mainly china sale ophthalmology increase drive initial uptake vabysmo partially compensate fall lucentis sale competitive pressure therapeutic area sale activasetnkase lower mainly unwind temporary stockpile distributor customer end finance report financial review roche group product sale pharmaceutical division sale change sale sale chf chf cer oncology perjeta tecentriq herceptin avastin kadcyla mabtherarituxan alecensa phesgo gazyvagazyvaro polivy erivedge total oncology neuroscience ocrevus evrysdi madopar total neuroscience immunology actemraroactemra xolair esbriet pulmozyme cellcept mabtherarituxan total immunology haemophilia hemlibra total haemophilia infectious disease ronapreve rocephin total infectious disease ophthalmology lucentis vabysmo total ophthalmology roche group financial review finance report pharmaceutical division sale continue change sale sale chf chf cer therapeutic area activasetnkase mircera total therapeutic area total sale total mabtherarituxan sale chf million chf million split oncology immunology therapeutic area ocrevus relapse form multiple sclerosis rm primary progressive multiple sclerosis ppm ocrevus regional sale change sale sale chf chf cer united states europe international total sale continuously grow demand indication growth drive new return patient high proportion sale come return patient europe international region ocrevus continue high uptake notably germany italy spain canada franchise perjeta herceptin kadcyla phesgo herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin perjeta regional sale change sale sale chf chf cer united states europe japan international total sale herceptin regional sale change sale sale chf chf cer united states europe japan international total sale finance report financial review roche group kadcyla regional sale change sale sale chf chf cer united states europe japan international total sale phesgo regional sale change sale sale chf chf cer united states europe international total sale sale franchise increase chf billion sale perjeta grow notably international region high demand china early metastatic breast cancer setting sale perjeta increase growth adjuvant setting largely offset reduction sale volume follow launch phesgo herceptin sale low result biosimilar erosion kadcyla sale increase drive usage early breast cancer set notable growth japan italy decrease sale kadcyla competitive pressure phesgo sale continue strong uptake europe notably france uk hemlibra haemophilia hemlibra regional sale change sale sale chf chf cer united states europe japan international total sale sale growth continue especially europe noninhibitor segment sale international region grow major market sale japan high market penetration tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc extensivestage small cell lung cancer sclc pdlpositive triplenegative breast cancer tnbc unresectable metastatic hepatocellular carcinoma hcc tecentriq regional sale change sale sale chf chf cer united states europe japan international total sale sale increase growth mainly europe sale higher drive new indication nsclc hcc europe growth mainly drive sclc tnbc indication notably france germany japan sales decline follow government price cut partly offset growth hcc indication roche group financial review finance report actemraroactemra rheumatoid arthritis form juvenile idiopathic arthritis giant cell arteritis car tcellinduce severe lifethreatening cytokine release syndrome covid actemraroactemra regional sale change sale sale chf chf cer united states europe japan international total sale sale decrease mainly international region drive low demand hospitalise patient covid avastin advanced colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma liver cancer combination tecentriq avastin regional sale change sale sale chf chf cer united states europe japan international total sale sale decrease region mainly europe continue impact biosimilar international region main driver sale decline biosimilar competition china xolair chronic spontaneous urticaria allergic asthma xolair regional sale change sale sale chf chf cer united states total sale sale increase drive growth chronic spontaneous urticaria indication xolair remain market leader large allergic asthma indication mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl pemphigus vulgaris pv rheumatoid arthritis ra certain type antineutrophil cytoplasmic antibody anca associate vasculitis mabtherarituxan regional sale change sale sale chf chf cer united states europe japan international total sale sale low biosimilar erosion region oncology immunology segmentsfinance report financial review roche group alecensa alkpositive nonsmall cell lung cancer nsclc alecensa regional sale change sale sale chf chf cer united states europe japan international total sale global uptake continue increase sale international region notably china main driver ronapreve treatment recently diagnose highrisk patient mild moderate covid ronapreve regional sale change sale sale chf chf cer europe japan international total sale roche collaborate regeneron pharmaceuticals inc regeneron develop manufacture distribute ronapreve neutralise antibody combination term agreement regeneron responsible distribution roche responsible distribution outside sale ronapreve increase drive sale japan activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sale change sale sale chf chf cer united states international total sale sale low mainly temporary stockpile distributor customer end evrysdi spinal muscular atrophy sma evrysdi regional sale change sale sale chf chf cer united states europe japan international total sale evrysdi continue strong uptake region drive europe international region roche group financial review finance report lucentis neovascular wet agerelate macular degeneration namd macular oedema follow retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sale change sale sale chf chf cer united states total sale sale decrease competitive pressure biosimilar version lucentis restrict label come market begin quarter esbriet idiopathic pulmonary fibrosis ipf esbriet regional sale change sale sale chf chf cer united states europe international total sale sale decline drive launch generic version second quarter reduce share new patient prescription vabysmo neovascular wet agerelate macular degeneration namd diabetic macular oedema dme vabysmo regional sale change sale sale chf chf cer united states europe japan international total sale sale new eye medicine show strong uptake follow approval january pharmaceutical division sale region change sale sale chf chf cer united states europe japan international china total sale finance report financial review roche group united states sale decline drive combined fall total mabtherarituxan herceptin avastin sale low sale actemraroactemra lucentis esbriet partly offset increase sale ocrevus vabysmo hemlibra tecentriq vabysmo show high initial uptake new patient patient switch medication achieve chf billion sale launch ocrevus sale increase drive new return patient demand hemlibra continue growth noninhibitor segment sale growth tecentriq sale increase continue growth new indication xolair sale increase growth chronic spontaneous urticaria indication sale phesgo continue strong uptake launch evrysdi show continue uptake launch sale growth actemraroactemra sale decrease low demand hospitalise patient covid esbriet sale decline mainly launch generic version second quarter lucentis sale decrease competitive pressure europe sale decline mainly drive base effect ronapreve exclude ronapreve sale grow cer sale new product offset impact biosimilar competition lead combined sale decline mabtherarituxan herceptin avastin evrysdi show high uptake mainly germany uk italy phesgo report strong momentum country france uk key growth driver sale growth ocrevus notably germany italy spain japan sale increase mainly result ronapreve sale chf billion support sale growth recently launch product include evrysdi polivy hemlibra enspryng offset impact biosimilar government price cut combine fall sale mabtherarituxan herceptin avastin arise biosimilar competition price cut japan impact portfolio international sale increase sale growth brazil canada sale china lower mainly drive biosimilar erosion mabtherarituxan herceptin avastin low sale rocephin partially offset continue sale growth alecensa gazyvagazyvaro perjeta covid restriction china certain negative impact sale product portfolio exclude china sales international region increase mainly drive high demand perjeta hemlibra ocrevus kadcyla operating result pharmaceutical division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product profitshare agreement total ifrs core basis royalty operating income increase cer royalty income low low royalty income lucentis income outlicense agreement increase result income ultomiris patent settlement effective march chugai alexion pharmaceuticals inc alexion fullyowne subsidiary astrazeneca plc enter settlement agreement resolve patent dispute company relate ultomiris ravulizumab term agreement alexion single payment usd million chugai amount payable party agreement include grant chugai alexion worldwide nonexclusive fully paidup licence respect ultomiris accordingly revenue chf million present income outlicense agreement roche group financial statement accordance roche establish core result concept treat core net income income product disposal include sale right rocaltrol china chf million sale global right valcyte chf million sale global right xeloda exclude china japan chf million profitshare income low reduction chf billion profitsharing agreement regeneron relate sale ronapreve profitshare income sale venclextavenclyxto increase chf million roche group financial review finance report pharmaceutical division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement amortisation commercial software intangible asset impairment property plant equipment rightofuse asset cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost decrease cer primarily low manufacturing cost drive favourable product mix impact base effect incremental production cost chf million arise response covid pandemic income chf million reversal idleplant impairment percentage sale cost sale decrease percentage point royalty expense higher drive increase sale certain royaltybearing product notably ocrevus evrysdi collaboration profitsharing expense decrease mainly low sale mabtherarituxan impairment charge intangible asset market product chf billion main item chf billion gavreto intangible asset low sale expectation addition impairment charge chf billion relate flatiron technology chf billion rozlytrek ignyta acquisition decrease amortisation charge intangible asset primarily attributable esbriet intangible asset fully amortise late global restructuring cost mainly related manufacturing network strategy review impact site include switzerland germany pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer percentage sale increase comparative period major marketing distribution activity include investment digital customer support ongoing launch notably vabysmo spend ocrevus tecentriq prelaunch activity ifrs basis cost decrease mainly restructuring cost transformation initiative sale affiliatesfinance report financial review roche group pharmaceutical division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer represent percentage sale oncology remain primary area research development cancer immunotherapy portfolio key driver neuroscience immunology ophthalmology represent significant area spend growth drive high investment spark therapeutic support investigational programme haemophilia b study relate pompe disease chugai show increase spending drive latestage investment oncology continue investment research development activity china offset decline latestage portfolio investment significantly lower covidrelated spending codevelopment regeneron chf million intangible asset impairment charge asset research development stage total chf billion major item charge chf billion partial impairment intangible asset spk novel gene therapy treatment haemophilia acquire spark therapeutic acquisition charge chf billion impairment intangible asset prm novel antifibrotic immunomodulator treatment idiopathic pulmonary fibrosis acquire promedior acquisition restructuring cost research development portfolio prioritisation programme mainly relate study closure cost additionally inlicense transaction business combination asset acquisition result intangible asset chf billion chf billion recognise section merger acquisition alliance transaction detail pharmaceuticals division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment rightofuse asset business taxis capital taxis general item general administration core basis global restructuring plan merger acquisition alliance transaction legal environmental case total ifrs basis core cost decrease cer percentage sale decrease administration cost low mainly low legal expense business taxis capital taxis decrease result low excise tax expense restructuring cost lower include cost baselkaiseraugst site income legal environmental case partial release certain legal provision base late development roche group financial review finance report roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical chugai pharmaceutical division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale external customer pharmaceutical division total core operating profit operating profit include elimination chf minus million unrealised intercompany gain roche pharmaceutical chugai chf minus million increase exchange rate japanese yen adverse impact approximately percentage point chugai result express swiss franc group consolidated result cer report japanese yen sale chugai external customer increase drive sale ronapreve sale division increase high sale hemlibra chugai roche pharmaceutical chugais core operating profit increase result income ultomiris patent settlement high gross profit sale external customer division partially offset low royalty income roche pharmaceutical high research development cost operate free cash flow chugai decrease mainly result increase trade receivable ronapreve sale december partially offset ultomiris patent settlement underlie operating performance financial position pharmaceutical division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivables payable net work capital property plant equipment rightofuse asset goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give finance report financial review roche group currency translation effect balance sheet amount compare start year swiss franc appreciate significantly japanese yen partially compensate depreciation swiss franc dollar result net negative translation impact exchange rate give net work capital net working capital increase cer trade receivable main driver increase trade receivables drive ronapreve sale japan december extend payment term certain product increase ocrevus sale growth time collection generally increase inventory drive ensure supply resilience notably actemraroactemra significant depletion inventory level previously high demand covid patient critical raw material give global supply scarcity rampup launch product notably vabysmo phesgo driver growth inventory net liability position receivablespayable increase low receivables regeneron profit share income longterm net operating asset overall longterm net operating asset decrease cer mainly low intangible asset slightly offset decrease provision intangible asset decrease result impairment charge explain section impairment goodwill intangible asset provision decrease recording restructure provision end utilisation restructuring provision capital expenditure include manufacture investment japan switzerland germany site development switzerland south san francisco chugais research facilities yokohama free cash flow pharmaceutical division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow sale page definition free cash flow detailed breakdown pharmaceutical division operate free cash flow decrease cer chf billion cash generation business measure operating profit net operating cash adjustment increase core operating profit increase difference mainly increase provision net working capital absorb additional chf billion cash drive increase trade receivables increase inventory reason describe financial position section capital expenditure low comparison major item describe financial position section investment intangible asset higher include payment intangible asset acquire end roche group financial review finance report diagnostic division operating result diagnostic division operating result change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operating income revenue cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow b operate free cash flow margin sale page definition core result b page definition free cash flowfinance report financial review roche group sale diagnostic division report sale chf billion increase cer growth routine testing compensate sale decrease low demand covidrelated product sale division base business increase region immunodiagnostic main growth driver sale covidrelate test decrease cer chf billion chf billion low demand covidrelated product sarscov rapid antigen test account approximately covidrelate sale sarscov rapid antigen test main growth driver point care customer area growth routine test main contributor increase sale core lab pathology lab customer area sale molecular lab customer area decrease lower covidrelate sale sarscov assay cobas range diabete care sale decrease drive base effect resolution rebate dispute diagnostic division sale customer area change sale sale chf chf cer core lab point care molecular lab diabetes care pathology lab total sale sale point care customer area include sale liat business poc molecular sale core lab customer area include sale life science alliance business previously show molecular lab customer area comparative information restate accordingly sale poc molecular chf million life science alliance chf million core lab customer area focus central lab provide diagnostic solution area immunoassay clinical chemistry custom biotech sale increase growth immunodiagnostic product cardiac oncology test growth clinical chemistry business sale custom biotech business low sale grow region large contribution come asiapacific emea region grow respectively point care customer area provide diagnostic solution immediately point care emergency room general practitioner practice directly patient include blood gas electrolyte bge test sale sarscov rapid antigen test report customer area main driver sale growth sale test concentrate asiapacific north america region molecular lab customer area focus molecular lab provide diagnostic solution detection monitor pathogen donor screen sexual health genomics sale decline lower covidrelate sale sarscov assay cobas range partly offset growth base business portfolio diabete care customer area provide diagnostic solution patient healthcare professional enable integrate personalised diabetes management sale decrease base effect resolution rebate dispute exclude sale remain stable continued contraction blood glucose monitoring market patient switch continuous glucose monitoring system particular major european market offset high demand emerge market pathology lab customer area focus pathology lab provide diagnostic solution tissue biopsy companion diagnostic target diagnostic aid choice specific therapy patient sale increase growth advance stain companion diagnostic business roche group financial review finance report diagnostic division sale region change sale sale chf chf cer europe middle east africa emea north america asiapacific china latin america total sale sale emea region decrease significant reduction covidrelate sale compare previous year partly offset growth immunoassay business north america sale growth drive sale sarscov rapid antigen test asiapacific sale high result increase sale sarscov rapid antigen test growth immunoassay business operating result diagnostic division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty operating income decrease cer drive base effect outlicensing agreement diabete care diagnostic division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense amortisation commercial software intangible asset impairment property plant equipment rightofuse asset cost sale core basis global restructuring plan amortisation intangible asset merger acquisition alliance transaction total ifrs basis core cost increase cer increase sale growth arise product mix drive increase sale volume sarscov rapid antigen test low volume sarscov pcr test high freight cost impairment property plant equipment incur connection atrisk manufacturing rampup rollout covidrelated product core cost sale ratio increase percentage point global restructuring cost decrease restructuring activity diabetes care prior periodfinance report financial review roche group diagnostic division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer result high distribution cost relate sarscov rapid antigen test partly offset low personnel expense core basis marketing distribution cost percentage sale decrease compare global restructuring cost decrease restructuring activity prior period notably diabete care diagnostic division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer digital solution main growth driver addition investment continue project sequence cardiac disease mass spectrometry percentage sale research development core cost increase diagnostic division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment rightofuse asset gain loss divestment subsidiary business taxis capital taxis general item general administration core basis global restructuring plan merger acquisition alliance transaction legal environmental case total ifrs basis core cost increase cer drive base effect general item sale tax refund prior year high administration cost shift reporting line certain support function percentage sale core cost increase merger acquisition alliance transaction cost include income chf million release contingent consideration provision roche group financial review finance report financial position diagnostic division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivables payable net work capital property plant equipment rightofuse asset goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc appreciate euro negative effect net operating asset diagnostic division result negative net translation impact exchange rate give net work capital net working capital increase cer drive increase inventory increase support growth division base business notably core lab customer area addition increase inbound shipment instrument end year recovery supply backlog decrease trade receivable low demand covidrelated test quarter compare decrease net liability receivablespayable come higher employeerelate accrual longterm net operating asset overall longterm net operating asset increase cer property plant equipment increase result instrument placement site investment germany goodwill intangible asset decrease cer follow regular amortisation charge partly offset contingent payment asset acquisition previously close provision low utilisation release restructure provision release contingent consideration provisionsfinance report financial review roche group free cash flow diagnostic division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow sale definition free cash flow detailed breakdown page operate free cash flow diagnostic division decrease cer chf billion chf billion cash generation business measure operating profit net operating cash adjustment decrease line core operating profit decrease net working capital absorb chf billion cash attributable high inventory describe financial position section capital expenditure increase instrument placement site investment germany roche group financial review finance report corporate operating result corporate operating result summary change chf chf cer administration business taxis capital taxis general item general administration cost core basis global restructuring plan legal environmental case total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow b operate free cash flow page definition core result b page definition free cash flow detailed breakdown administration cost higher relate cost transfer corporate function general item decrease mainly low project cost overall net net work capital low increase payable change longterm net operating asset utilisation provision ongoing environmental remediation activity nutley grenzach germany corporate operating free cash flow show increase outflow drive movement net work capital increase capital expenditurefinance report financial review roche group foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer chf change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy compare swiss franc weak dollar strong euro japanese yen net impact express swiss franc compare constant exchange rate percentage point sale percentage point core operating profit percentage point ifrs net income core ep sensitivity group sale core operating profit change average foreign currency exchange rate swiss franc show table currency sensitivity impact increase average exchange rate sale core operating profit versus swiss franc chf chf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany chugais revenues cost denominate japanese yen roche group financial review finance report treasury taxation result treasury taxation result change change chf chf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position net debt lease liability pension income taxis equity investment derivative net collateral net interest payable associate company net total net asset liability free cash flow b treasury activity taxis pay total page definition core result b page definition free cash flow financing cost core financing cost chf million increase cer compare interest expense debt increase cer chf million issuance debt december february march september increase interest rate affect cost shortterm borrowing commercial paper analysis financing cost give note annual financial statementsfinance report financial review roche group financial income expense core financial income expense net expense chf million compare net expense chf million core net income equity security reflect fair value change roche venture fund investment net loss chf million net loss chf million net foreign exchange result reflect hedging cost gain loss unhedged position net loss chf million net loss chf million loss net monetary position hyperinflationary economy argentina trkiye chf million loss chf million analysis financial income expense give note annual financial statement income taxis group effective core tax rate increase percentage point increase mainly impact resolution tax dispute reduce group effective core tax rate percentage point compare percentage point ifrs result see effective tax rate increase percentage point addition core impact mention impairment intangible asset tax deductible increase ifrs tax rate detail group income tax expense relate balance sheet position give note annual financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate chf chf chf chf group effective tax rate core basis global restructuring plan goodwill intangible asset merger acquisition alliance transaction legal environmental case pension plan settlement normalisation equity compensation plan tax benefit group effective tax rate ifrs basis financial position decrease net debt free cash flow chf billion partly offset dividend payment chf billion chf billion bridge loan facility draw finance share repurchase novartis fully repay partly proceed new debt issuance partly internal cash generation new debt issue refinance bridge loan facility usd billion issue december chf billion issue february usd billion issue march debt chf billion issue september lease liability decrease chf billion regular payment net pension liability low follow increase discount rate net tax asset increase mainly taxis pay exceed income tax expense partially offset defer tax effect pension equity compensation plan december group hold equity investment market value chf billion consist holding biotechnology pharmaceutical company acquire licensing transaction scientific collaboration investment roche venture fund net derivative liability increase chf billion result interest rate exchange rate movement free cash flow net cash outflow treasury activity chf billion compare outflow chf billion mainly high interest payment follow increase interest rate affect cost shortterm borrowing total taxis pay chf billion increase cer high payment tax requirement mandatory capitalisation research development expense effective high payment japan roche group financial review finance report cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow treasury activity taxis pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow treasury activity taxis pay free cash flow definition free cash flow detailed breakdown page operate free cash flow decrease cer chf billion mainly increase net work capital absorb additional chf billion cash drive increase trade receivables pharmaceutical division inventory division free cash flow chf billion decrease cer result lower operating free cash flow high shortterm borrowing cost increase interest rate high tax payment notably japanfinance report financial review roche group net debt millions chf january cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow dividend payment transaction equity instrument merger acquisition net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt december cash cash equivalent marketable security longterm debt shortterm debt net debt end period definition net debt net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen total net debt position group december chf billion decrease chf billion december decrease free cash flow chf billion exceed chf billion annual dividend payment chf billion transaction equity instrument chf billion currency translation dividend payment low cancellation february share acquire novartis transaction equity instrument relate purchase connection group equity compensation plan payment hedge collateral arrangement consist foreign currency forwards chf billion net collateral payment chf billion roche group financial review finance report contractual obligation commitment group obligation commitment set table carry value show consolidated balance sheet potential obligation show discount riskadjuste note amount denominate foreign currency translate swiss franc december exchange rate provision legal environmental matter include timing cash outflow uncertain contingent development matter question contractual obligation commitment december millions chf potential obligation carry year year year year total value onbalance sheet debt bond note debt contingent consideration account payable noncurrent liability current liability unfunde define benefit plan total onbalance sheet commitment offbalance sheet capital commitment property plant equipment leasing commitment contract manufacturing commitment alliance collaboration commitment total offbalance sheet commitment total contractual commitment reference note annual financial statement debt consist mainly bond note include principal interest group debt instrument debt mainly commercial paper carry value discount base interest rate inherent instrument contingent consideration consist potential payment arise merger acquisition carry value riskadjuste discount unfunded define benefit plan mainly pension plan group german affiliate fully reserve pension obligation selffinance local affiliate operation carry value discount future company contribution group fund plan show table capital commitment property plant equipment noncancellable commitment purchase construction mainly roche site basel switzerland south san francisco penzberg germany new manufacturing site chugai japan leasing commitment major noncancellable commitment sign lease agreement lease term start mainly relate site foundation medicine boston genentech south san franciscofinance report financial review roche group contract manufacturing commitment future minimum takeorpay commitment purchase inventory arise group major longterm agreement external contract manufacturing organisation cmos alliance collaboration commitment potential upfront milestone payment group inlicense alliance arrangement intangible asset purchase agreement include asset acquisition potential payment alliance partner asset purchase agreement year include assume project currently development successful potential payment year include asset purchase agreement pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan chf million chf million plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource expense group define benefit plan chf million chf million define benefit plan fund status balance sheet position chf chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group fund define benefit plan increase compare start year come reduction define benefit obligation increase discount rate relevant region compare end partly offset decrease fair value plan asset limit asset recognition arise result surplus base current market assumption certain swiss pension plan recognisable ifrs funding status pension fund monitor local pension fund governance body closely review group level unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation unfunded liability plan decrease increase eurozone discount rate partly offset increase eurozone inflation rate detail group pension postemployment benefit give note annual financial statement roche group financial review finance report roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare companiesa total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate cer roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group chf term cer development roche share price influence negative news flow research development pipeline expect decline covidrelated sale december roche repurchase million roche share hold novartis total consideration chf billion repurchased share report treasury share december cancel february necessary legal procedure complete healthcare sector outperform world equity market impact strong inflation rise interest rate growth swiss market index smi slightly trail major index roche share outperform smi roche nonvoting equity securities underperform smi peer group abbott abbvie amgen astrazeneca bristolmyers squibb danaher glaxosmithkline johnson johnson lilly medtronic merck co novartis novo nordisk pfizer roche sanofi total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source refinitiv eikon datum roche peer index rebase january peer index convert swiss franc daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer indexfinance report financial review roche group propose dividend board director propose increase dividend chf share nonvoting equity security chf approval annual general meeting th consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security chf billion chf billion dividend proposal result payout ratio base core net income base price end dividend yield roche share yield nonvoting equity security information roche security give page information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note annual financial statement payout ratio calculate dividend share divide core earning share debt issuance new debt february group complete offer chf billion fix rate note issue tranche coupon mature november february march group complete offer usd billion fix rate note issue tranche coupon mature march march march group complete offer usd billion float rate note issue tranche rate equal secure overnight financing rate sofr plus margin note mature september march september group complete offer chf billion fix rate bond issue tranche coupon mature june september group receive total aggregate net proceed chf billion issuance sale note roche group financial review finance report redemption debt date september group redeem notes outstanding chf billion effective interest rate note date november group redeem notes outstanding chf billion effective interest rate note combine cash outflow chf billion gain loss record redemption debt maturity maturity schedule group bond note outstanding december show table bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf total total translate december exchange rate group plan meet debt obligation exist liquid fund cash generate business operation free cash flow chf billion chf billion include cash generate operation payment interest taxis shortterm financing requirement group commercial paper program issue usd billion unsecured commercial paper note commit credit line usd billion available backstop line commercial paper note total usd billion outstanding december usd billion longerterm financing group maintain high longterm investmentgrade credit rating aa standard poor aa moodys aa fitch facilitate efficient access international capital market information group debt give note annual financial statementsfinance report financial review roche group financial risk december group net debt position chf billion chf billion financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt repayment liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security chf total chf total cash cash equivalent money market instrument debt security equity security total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group chf billion cash fix income marketable security remain high invest aaaa range group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position bad debt expense overdue receivable remain relatively low level liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year free cash flow chf billion compare chf billion roche group continue enjoy high longterm investmentgrade credit rating aa standard poor aa moodys aa fitch time roche rate high available shortterm rating agency event financing requirement credit rating roche group permit efficient access international capital market include commercial paper market group commit credit line financial institution total usd billion available backstop line commercial paper program december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var increase december reflect bond issuance interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity group use interest rate derivative manage interest raterelate exposure financial result information financial risk management financial risk var methodology include note annual financial statement roche group financial review finance report international financial reporting standard roche group international financial reporting standard ifrs report consolidated result new revise standard apply group implement minor amendment exist standard interpretation material impact group overall result financial position note annual financial statement detailsfinance report roche group consolidate financial statement roche group roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche group roche group consolidated financial statement finance report roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf finance report roche group consolidate financial statement roche group roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income oci remeasurement define benefit plan fair value change equity investment fair value oci item reclassify income statement fair value change debt security fair value oci cash flow hedge currency translation foreign operation item reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche group roche group consolidated financial statement finance report roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment rightofuse asset goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity finance report roche group consolidate financial statement roche group roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product operate cash flow income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination asset acquisition divestment subsidiary interest receive pay dividend receive marketable security investment sale equity security debt security purchase equity security debt security sale purchase money market instrument time account month net invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement interest pay principal portion lease liability pay dividend pay share repurchase equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche group roche group consolidated financial statement finance report roche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement net change fair value financial asset fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend share repurchase equity compensation plan net transaction equity change noncontrolle interest december year end december january net income recognise income statement net change fair value financial asset fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend share capital reduction equity compensation plan net transaction equity change noncontrolle interest december finance report note roche group consolidate financial statement roche group note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist performance obligation satisfy different time contract enter diagnostic division typically include performance obligation instrument include provide leasing arrangement reagent consumable service instrument sell cash sale transaction discount price instrument provide operating lease arrangement entire lease revenue variable subject subsequent reagent sale major source estimation uncertainty relate measurement sale net discount relate obligation include standalone selling price require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise outlicense agreement entered obligation include commitment conduct research latestage development regulatory approval comarketing manufacturing settle combination upfront payment milestone payment license fee reimbursement service provide consider commitment single performance obligation separate one scope ifrs revenue contract customer straightforward require judgement depend conclusion result revenue calculate inception recognise spread term long performance obligation major source estimation uncertainty relate measurement sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim relate sale december group chf million provision accrual expect sale return chargeback rebate include medicaid similar rebate country chf million provision accrual relate pharmaceutical business amount chf million chf million chf million chf million associate expect sale return estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment roche group note roche group consolidated financial statement finance report business combination group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest consideration transfer business combination management judgement particularly involve assessment net asset acquire constitute business recognition fair value measurement intellectual property inventory contingent liability contingent consideration make assessment management apply judgement consider underlying economic substance item concern addition contractual term consider appropriate result judgement management apply optional concentration test set ifrs business combination aid assessment transaction represent business combination simply substance purchase single asset group similar asset impairment property plant equipment rightofuse asset goodwill intangible asset december group chf million property plant equipment note chf million rightofuse asset note chf million goodwill note chf million intangible asset note goodwill intangible asset available use review annually impairment property plant equipment rightofuse asset intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate estimate relate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lowerthananticipate product sale lead short useful life impairment impairment financial asset december group chf million allowance doubtful account trade lease receivable note key estimate allowance doubtful account mainly relate risk default expect loss rate make estimate input select calculate allowance doubtful account base company past experience exist market condition forwardlooke estimate end reporting period pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation key estimate require measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation chf million note actuarial assumption estimate differ materially actual result change market economic condition long short lifespan participant change factor assess difference impact define benefit plan asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate reliable estimate provision record contingent liability disclose material december group chf million legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently uncertain highly complex nature legal case estimate change substantially time new fact emerge legal case progress environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group chf million environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently uncertain assumption require relate detection previously unknown contamination method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group chf million contingent consideration provision note total potential payment contingent consideration arrangement business combination chf million note key estimate require determine amount expect payment provide consider possible scenario forecast sale performance criterion pay scenario probability scenario discount net present value estimate change substantially time new fact emerge scenario developsfinance report note roche group consolidate financial statement roche group income taxis december group current income tax net liability chf million defer tax net asset chf million note major source estimation uncertainty relate calculation current defer tax asset liability estimate base interpretation exist tax law regulation tax position uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience factor impact estimate current defer tax balance include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning lease group lessee key judgement include assess arrangement contain lease determine lease term assess contract contain lease require judgement depends specify asset group obtain substantially economic benefit use asset group right direct use asset order determine lease term judgement require extension termination option assess fact circumstance create economic incentive exercise extension option exercise termination option estimate include calculate discount rate base incremental borrowing rate december group chf million rightofuse asset chf million lease liability note group lessor treatment leasing transaction mainly determine lease consider operating finance lease require judgement make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover judgemental assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement case require judgement management assessment group control significant influence company consolidated subsidiary account associate company make judgemental assessment management consider underlie economic substance transaction addition contractual term impact covid pandemic group assess certain accounting matter generally require consideration forecast financial information take account potential future impact covid pandemic accounting matter assess include limited group provision product return allowance doubtful account trade lease receivables inventory allowance carry value goodwill intangible asset property plant equipment continue negative impact pandemic impact matter significant impact area assess group annual financial statement group continue monitor area increase judgement risk material change roche group note roche group consolidated financial statement finance report operating segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis legal safety environmental service subdivisional information present roche pharmaceutical chugai operate segment pharmaceutical division divisional information millions chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination asset acquisition addition property plant equipment addition rightofuse asset addition intangible asset total research development research development cost segment information depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset impairment goodwill impairment intangible asset inventory fair value adjustment equity compensation plan expense finance report note roche group consolidate financial statement roche group pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination result division operate profit capital expenditure business combination asset acquisition addition property plant equipment addition rightofuse asset addition intangible asset total research development research development cost elimination cost division total segment information depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset impairment goodwill impairment intangible asset inventory fair value adjustment equity compensation plan expense roche group note roche group consolidated financial statement finance report net asset millions chf asset liability net asset december net operating asset pharmaceutical diagnostic corporate total current income tax net asset liability defer tax net asset liability define benefit plan net asset liability lease liability marketable security cash cash equivalent debt net asset liability total net asset net operating asset pharmaceutical subdivisional information million chf asset liability net asset december roche pharmaceutical chugai elimination division pharmaceutical division finance report note roche group consolidate financial statement roche group information geographical area millions chf revenue external customer noncurrent asset royaltie property plant goodwill sale operate income equipment rightofuse asset ntangible asset switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue major customer total national wholesale distributor represent approximately group sale national wholesale distributor mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenue roche pharmaceutical operating segment residual diagnostic operating segment roche group note roche group consolidated financial statement finance report revenue disaggregate revenue information disaggregation revenue millions chf revenue revenue contract revenue contract revenue customer source total customer source total pharmaceutical division sale therapeutic area oncology neuroscience immunology haemophilia infectious disease ophthalmology therapeutic area sale royalty income income outlicense agreement income disposal product profitshare agreement royalties operate income diagnostic division sale customer area core lab point care molecular lab diabetes care pathology lab sale royalty income income outlicense agreement income disposal product royalty operating income total sale point care customer area include sale liat business poc molecular sale core lab customer area include sale life science alliance business previously show molecular lab customer area comparative information restate accordingly sale poc molecular chf million life science alliance chf million revenue source primarily relate lease revenue collaboration revenue counterparty consider customer income profitshare agreementsfinance report note roche group consolidate financial statement roche group grosstonet sale reconciliation pharmaceutical division grosstonet sale reconciliation pharmaceutical division show table company diagnostic division similar reconciling item low amount pharmaceutical division sale grosstonet reconciliation million chf gross sale government regulatory mandatory price reduction contractual price reduction cash discount customer return reserve net sale government regulatory mandatory price reduction consist mandatory price reduction major element b drug discount program medicaid plan total usd billion equivalent chf billion usd billion equivalent chf billion contractual price reduction include rebate chargeback result contractual agreement primarily volume base performance base cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivable note sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability note provision sale return record balance sheet provision note contract balance receivables millions chf account receivable current receivables contract customer noncurrent receivables contract customer total receivable current receivable mainly include royalty licensing receivable december total receivables include lease receivables consider receivables contract customer contract asset millions chf accrue income contract cost total contract asset roche group note roche group consolidated financial statement finance report contract liability millions chf defer income noncurrent defer income current total contract liability movement contract liability millions chf january business combination revenue recognise include contract liability balance begin year increase cash receive receivable exclude amount recognise revenue year currency translation effect december revenue recognise relation performance obligation satisfy previous year increase revenue recognise chf million decrease revenue chf million relate performance obligation satisfy previous period mainly adjustment sale deduction provision accrual expect sale return chargeback allowance respect previous year remain performance obligation partially unsatisfie longterm contract remain performance obligation partially unsatisfie longterm contract include defer income relate amount group expect receive good service transfer customer exist noncancellable enforceable contract mainly associate contract diagnostic division minimum purchase commitment related reagent consumable previously sell instrument monitor maintenance service contract original duration year group elect practical expedient disclose transaction price remain performance obligation end report period point time group expect recognise sale transaction price allocate contract partially unsatisfie performance obligation millions chf contract liability hold contract liability hold total thereof expect recognise revenue year year year total finance report note roche group consolidate financial statement roche group net financial expense financing cost millions chf interest expense amortisation debt discount fair value loss treasury lock designate cash flow hedge transfer oci net gain loss redemption repurchase bond note discount unwind include effect discount rate change net interest cost define benefit plan interest expense lease liability total financing cost financial income expense millions chf net gain loss equity investmentssecuritie fair value profit loss net income expense equity investmentssecuritie interest income expense debt security fair value oci amortise cost net gain loss sale debt security fair value oci net gain loss debt investmentssecuritie fair value profit loss net interest income expense income debt investmentssecuritie net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss gain loss net monetary position hyperinflationary economy net financial income expense associate total financial income expense roche group note roche group consolidated financial statement finance report net financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense hyperinflationary economy group consider argentina july trkiye april hyperinflationary economy context ias financial report hyperinflationary economy cumulative inflation index exceed argentina year measure national wholesale price index sistema de ndice de precio mayorista trkiye measure consumer price index publish turkish statistical institute accordingly group review reporting affiliate argentina trkiye necessary restate line ia potential adjustment result application ias significant impact group operate result balance sheet adjustment record gain loss net monetary position loss chf million result loss purchasing power positive net monetary position group affiliate argentina trkiye loss chf million group affiliate argentinafinance report note roche group consolidate financial statement roche group income taxis income tax expense millions chf current income taxis defer taxis total income tax expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate stable significant change local tax rate tax jurisdiction group operate group effective tax rate increase mainly low effect resolution tax dispute compare impairment intangible asset tax deductible group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development tax credit deduction state tax impact tax unremitted earning resolution tax dispute prioryear difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity chf million chf million income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately chf million chf million record tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan equity investment fair value oci debt security fair value oci cash flow hedge currency translation foreign operation comprehensive income roche group note roche group consolidated financial statement finance report income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liabilitie current income tax liability include accrual uncertain tax position current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect movement net current income tax asset liability december defer taxis movement recognise net asset liability millions chf property plant equipment rightofuse intangible define temporary asset asset benefit plan difference total year end december january business combination asset acquisition charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december year end december january business combination asset acquisition charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december finance report note roche group consolidate financial statement roche group net defer tax asset temporary difference mainly relate accrue liability include lease liability provision unrealise profit inventory defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable chf tax rate chf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste purpose financial statement total unremitted earning group regard permanently reinveste purpose financial statement chf billion december chf billion roche group note roche group consolidated financial statement finance report merger acquisition note include transaction account business combination asset acquisition asset acquisition acquisition legal entity qualify business combination ifrs include acquisition value acquire company largely consist right single asset eg product technology group similar asset cash consideration pay asset acquisition transaction date subsequent additional contingent payment achievement performancerelate development milestone present line cash flow asset acquisition disclose separately subsequent consideration performancerelate development milestone transaction treat asset acquisition recognise intangible asset specific milestone achieve recognition criterion meet business combination group complete business combination business combination genmark diagnostics inc april group acquire control interest genmark diagnostics inc genmark publicly own company base carlsbad california list nasdaq genmark report diagnostic division total consideration usd million pay cash tib molbiol group december group acquire interest tib molbiol group tib molbiol privately own group base berlin germany tib molbiol report diagnostic division total consideration eur million pay cash protocol inc december group acquire control interest protocol inc protocol privately own company base salt lake city utah protocol report pharmaceutical division total consideration usd million pay cash identifiable asset acquire liability assume set table business combination net asset acquire millions chf genmark tib molbiol protocol total property plant equipment rightofuse asset intangible asset product intangible use intangible defer tax asset inventory cash cash equivalent marketable security longterm debt defer tax liability noncurrent liability lease liability longterm liability net asset liability net identifiable asset goodwill total consideration cash total consideration finance report note roche group consolidate financial statement roche group genmark intangible asset mainly relate eplex system design support broad range molecular diagnostic sampletoanswer test compact easytouse workstation selfcontaine disposable test cartridge fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value product intangible asset genmark eplex technology calculate riskadjusted discount rate present value tib molbiol product intangible asset protocol first intangible calculate riskadjusted discount rate respectively valuation perform independent valuer genmark goodwill represent technological capability multiplex molecular diagnostic solution furthermore represent control premium acquire workforce expect synergy notably area manufacture commercialisation tib molbiol protocol goodwill represent control premium acquire workforce expect synergies goodwill genmark tib molbiol transaction allocate diagnostic customer area cashgenerate unit goodwill protocol transaction allocate roche pharmaceutical cashgenerating unit goodwill expect deductible income tax purpose account receivable comprise gross contractual amount chf million genmark acquisition chf million tib molbiol acquisition expect collectable date acquisition directly attributable transaction cost chf million report diagnostic operating segment chf million roche pharmaceutical operating segment general administration expense month end december genmark contribute revenue chf million net loss tax chf million result report diagnostic division report molecular lab customer area group impact tib molbiol acquisition result diagnostic division report molecular lab customer area group material acquisition occur january management estimate genmark tib molbiol contributed revenue approximately chf million net loss include intangible asset amortisation tax approximately chf million information provide illustrative purpose necessarily indicative result combine group occur genmark tib molbiol actually acquire beginning year indicative future result combine group impact protocol acquisition result pharmaceutical division group material cash flow business combination business combination net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company total net cash outflow roche group note roche group consolidated financial statement finance report asset acquisition good therapeutics inc september group acquire control interest good therapeutics inc good therapeutic privately own company base seattle washington acquisition group gain access good therapeutic pdregulate il programme good therapeutic report pharmaceutical division cash consideration pay acquisition date usd million additional contingent payment base achievement performancerelate milestone asset acquisition net asset acquire millions chf good herapeutic intangible asset product intangible available use defer tax asset cash cash equivalent net asset liability net identifiable asset fair value previously hold equity interest total consideration cash total consideration asset acquisition group complete asset acquisition cash flow asset acquisition asset acquisition net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay cash acquire company contingent payment relate previous acquisition total net cash outflow asset acquisition previously close group record addition product intangible asset relate contingent payment achievement performancerelate milestone chf million chf million furthermore group contingent payment chf million related product intangible asset recognise december finance report note roche group consolidate financial statement roche group global restructuring plan pharmaceutical division initiate portfolio prioritisation programme group continue implementation global restructuring plan initiate prior year global restructuring plan cost incur millions chf global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost business process transformation simplify system landscape streamline process complexity incur employeerelate cost chf million chf million reorganisation expense chf million chf million transformation multiyear crossdivisional programme drive efficiency gain manufacturing network strategy review pharmaceutical division incur site closure cost chf million chf million relate site switzerland germany additionally pharmaceutical division portfolio prioritisation programme incur cost chf million mainly relate closure study major item global restructuring cost employeerelate cost business transformation initiative pharmaceutical division strategy plan diagnostic division notably diabete care site development baselkaiseraugst site switzerland roche group note roche group consolidated financial statement finance report global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment reversal property plant equipment rightofuse asset accelerate depreciation property plant equipment rightofuse asset gain loss disposal property plant equipment rightofuse asset site closure cost total site closure cost divestment product business gain loss divestment subsidiary gain loss divestment product business total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost finance report note roche group consolidate financial statement roche group global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total cost total operating segment roche pharmaceutical chugai diagnostic corporate total cost roche group note roche group consolidated financial statement finance report property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january business combination addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value finance report note roche group consolidate financial statement roche group classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment reversal charge impairment property plant equipment mainly relate global restructuring plan note pharmaceutical division report impairment reversal property plant equipment chf million net idleplant impairment reverse half result income chf million partially offset impairment property plant equipment include atrelated asset chf million impairment charge chf million incur diagnostic division mainly connection atrisk manufacturing rampup rollout covidrelated product reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment december machinery equipment original cost chf billion chf billion net book value chf billion chf billion lease party note capital commitment group noncancellable capital commitment purchase construction property plant equipment totalling chf billion chf billion roche group note roche group consolidated financial statement finance report goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical roche pharmaceutical product transaction chugai total pharmaceutical division diagnostic customer area diabete care customer area divisional goodwill total diagnostic division cashgenerating unit allocate goodwill pharmaceutical division basis use cashgenerating unit allocate goodwill pharmaceutical division follow roche pharmaceutical operating segment goodwill arise broad type transaction strategic transaction transformative effect division technology transaction acquire technology range area application product transaction acquire product typically limited synergistic benefit outside immediate product therapeutic area cashgenerating unit goodwill arise strategic transaction roche pharmaceutical operating segment cashgenerating unit goodwill arise technology transaction roche pharmaceutical operating segment acquire technology permanently cease operate treat disposal business case goodwill deem dispose fully impair cashgenerating unit goodwill arise product transaction small identifiable group asset relate revenue relate cost arise development commercialisation product question synergistic benefit product therapeutic area revenue cost correspond asset product take account acquire product permanently cease generate economic benefit treat disposal business case goodwill deem dispose fully impair chugai separate operating segment group financial report separate cashgenerating unit goodwill allocatedfinance report note roche group consolidate financial statement roche group group allocate goodwill roche pharmaceutical operating segment list strategic transaction consist genentech foundation medicine flatiron health spark therapeutic technology transaction consist therapeutic human polyclonal dutalys santaris product transaction consist glycart tanox diagnostic division basis use cashgenerating unit allocate goodwill diagnostic division follow diagnostic division goodwill arise broad type transaction strategic transaction transformative effect division technology transaction acquire technology range area application product transaction acquire product synergistic benefit wide business limit synergistic benefit outside immediate product therapeutic area cashgenerating unit goodwill arise strategic transaction diagnostic division cashgenerating unit goodwill arise technology transaction diagnostic customer area diabetes care customer area acquire technology permanently cease operate treat disposal business case goodwill deem dispose fully impair cashgenerating unit goodwill arise product transaction small identifiable group asset relate revenue relate cost arise development commercialisation product question synergistic benefit product business revenue cost correspond asset product take account cashgenerating unit diagnostic customer area diabete care customer area acquire product permanently cease generate economic benefit treat disposal business case goodwill deem dispose fully impair group allocate goodwill roche diagnostic operating segment list strategic transaction consist corangeboehringer mannheim technology transaction consist viewic diagnostic customer area mysugr diabetes care customer area product transaction diagnostic customer area consist igen bioveris ventana pvt iquum genmark tib molbiol product transaction diabetes care customer area consist disetronic medingo impairment charge impairment goodwill impairment charge impairment goodwill roche group note roche group consolidated financial statement finance report value use value use calculate discount expect cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate group weight average cost capital cashgenerating unit integrate operation large part group derive capital asset pricing model data capital market include government twentyyear bond assess value use cash flow projection base recent longterm forecast approve management longterm forecast include management late estimate sale volume pricing production operating cost assume significant change organisation key assumption calculation period cash flow projection include longterm forecast terminal value growth rate discount rate key assumption valueinuse calculation period terminal period terminal cash flow value discount rate cash flow value discount rate projection growth rate tax projection growth rate tax pharmaceutical division year na year na diagnostic division year year goodwill relate roche pharmaceutical product transaction productspecific period cash flow projection cashgenerating unit terminal value growth respective rate exceed longterm project growth rate relevant market fair value cost disposal goodwill arise chugai acquisition fair value cost disposal determined reference publicly quote price chugai share sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai decrease publicly quote share price result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable amount december finance report note roche group consolidate financial statement roche group intangible asset intangible asset movement carry value asset millions chf product product ntangible intangible use available use intangible total january cost accumulate amortisation impairment net book value year end december january business combination asset acquisition addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination asset acquisition addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group roche group note roche group consolidated financial statement finance report significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use rozlytrek ignyta acquisition roche pharmaceutical year genmark acquisition diagnostic year xofluza shionogi inlicense transaction roche pharmaceutical year kapa acquisition diagnostic year susvimo forsight vision acquisition roche pharmaceutical year product intangible available use sarepta inlicense transaction roche pharmaceutical na spk haemophilia gene therapy spark therapeutic acquisition roche pharmaceutical na inflazome acquisition roche pharmaceutical na stratos genomic acquisition diagnostic na good therapeutic acquisition roche pharmaceutical na biontech inlicense transaction roche pharmaceutical na dicerna inlicense transaction roche pharmaceutical na intangible technology intangible use adaptive inlicense transaction roche pharmaceutical year classification intangible asset amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset december internally generate intangible asset relate commercial software amount chf million chf million include intangible group internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful livesfinance report note roche group consolidate financial statement roche group intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination asset acquisition separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower thananticipate sale product capitalise right result shorten useful life impairment impairment charge pharmaceutical division impairment charge total chf million record major item relate charge chf million impairment inlicense gavreto product intangible asset low sale expectation asset concern amortise fully write charge chf million partial impairment product intangible asset spk novel gene therapy treatment haemophilia acquire spark therapeutic acquisition impairment result revise sale expectation asset concern amortise write estimate recoverable chf million charge chf million impairment product intangible asset prm novel antifibrotic immunomodulator treatment idiopathic pulmonary fibrosis acquire promedior acquisition impairment decision stop development follow datum assessment asset concern amortise fully write charge chf million partial impairment product intangible asset relate technology acquire flatiron acquisition impairment result reduce sale expectation asset concern write estimate recoverable chf million intangible asset continue amortise remain estimate useful life year charge chf million partial impairment product intangible asset rozlytrek acquire ignyta acquisition low sale expectation asset concern write estimate recoverable chf million intangible asset use continue amortise remain estimate useful life year charge chf million impairment product intangible asset relate foundation medicine technology impairment result increase competition reduce sale expectation asset concern amortise fully write charge chf million partial impairment product intangible asset spk novel gene therapy treatment haemophilia b acquire spark therapeutic acquisition impairment result revise sale expectation asset concern amortise write estimate recoverable chf million charge chf million follow clinical datum assessment decision stop development cd acquire tusk therapeutic acquisition asset concern amortise fully write charge chf million decision stop development compound relate collaboration alliance partner asset concern amortise fully write charge chf million follow clinical datum assessment decision stop development nlrp inhibitor acquire jecure therapeutic acquisition asset concern amortise fully write charge chf million partial impairment product intangible asset luxturna acquire spark therapeutic acquisition impairment result reduce sale expectation asset concern write estimate recoverable chf million intangible asset continue amortise remain estimate useful life year charge chf million impairment product intangible asset spk novel gene therapy treatment lateonset pompe disease acquire spark therapeutic acquisition impairment result change timeline underlie development programme lead reduce sale expectation asset concern amortise fully write roche group note roche group consolidated financial statement finance report impairment charge pharmaceutical division impairment charge total chf million record major item relate charge chf million impairment intangible asset follow plan return right licence atea pharmaceutical announcement termination strategic collaboration asset concern amortise fully write charge chf million partial impairment compound develop alliance partner mainly drive reduced sale expectation asset concern amortise write estimate recoverable chf million charge chf million partial impairment product intangible asset luxturna acquire spark therapeutic acquisition impairment result reduce sale expectation asset concern write estimate recoverable chf million intangible asset continue amortise remain estimate useful life year charge chf million partial impairment intangible asset spk acquire spark therapeutic acquisition impairment result change plan regulatory timeline revise sale expectation asset concern amortise write estimate recoverable chf million charge chf million decision stop development compound alliance partner asset concern amortise fully write charge chf million decision stop collaboration project alliance partner follow datum assessment asset concern amortise fully write charge chf million decision stop collaboration project alliance partner asset concern amortise fully write previously record impairment compound development partially reverse income chf million record asset concern write estimate recoverable value chf million follow clinical datum assessment asset concern amortise follow clinical datum assessment half impairment charge chf million record compound development review clinical data result second half impact programme impairment fully reverse potential commitment alliance collaboration intangible asset purchase agreement year group party inlicense alliance arrangement intangible asset purchase agreement include asset acquisition arrangement purchase agreement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment potential payment year set table figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration purchase payment december millions chf pharmaceutical diagnostic group year year year total finance report note roche group consolidate financial statement roche group inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total chf billion chf billion inventory writedown year result expense chf million chf million account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance withhold settlement total account receivable allowance doubtful account movement recognise allowance millions chf january additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense record marketing distribution cost total chf million expense chf million roche group note roche group consolidated financial statement finance report marketable security marketable security millions chf equity security fair value profit loss debt security fair value oci debt security fair value profit loss money market instrument fair value oci time account month amortise cost total marketable security marketable security hold fund management purpose primarily denominate dollar euro swiss franc money market instrument contract mature year december debt security contract maturity million chf year year year total debt security cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent finance report note roche group consolidate financial statement roche group noncurrent asset noncurrent asset millions chf equity investment fair value oci equity debt investment fair value profit loss loan receivable restrict cash receivables contract customer receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset equity investment designate fair value oci mainly investment private company pharmaceutical sector hold group strategic alliance effort current asset current asset millions chf accrue interest income derivative financial instrument cash collateral receivables receivables contract customer receivables total financial current asset prepaid expense accrue income taxis recoverable asset total nonfinancial current asset total current asset roche group note roche group consolidated financial statement finance report account payable account payable million chf trade payable taxis payable dividend payable payable total account payable noncurrent liability noncurrent liability millions chf defer income lease liability longterm liability total noncurrent liability current liability current liability millions chf defer income lease liability accrue payroll relate item interest payable derivative financial instrument cash collateral payable accrue chargeback allowance separately payable accrue royalty commission accrue liability total current liability finance report note roche group consolidate financial statement roche group provision contingent liability provision movement recognise liability millions chf contingent legal environmental restructuring consideration p rovision provision provision provision p rovision total year end december january additional provision create unused amount reverse utilise discount unwind include effect discount rate change business combination acquire company defer consideration contingent consideration asset acquisition currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind include effect discount rate change business combination acquire company defer consideration contingent consideration asset acquisition currency translation effect december current noncurrent december expect outflow resource year year year year december chf million provision utilise chf million entirely include cash flow operating activity chf million remaining chf million include cash flow business combination payment deferred contingent consideration arrangement note roche group note roche group consolidated financial statement finance report legal provision legal provision relate number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict regular review litigation matter management reassess provision record certain litigation matter base development litigation net release legal provision chf million net increase chf million net income legal case include general administration chf million net expense chf million detail major legal case outstanding disclose environmental provision provision environmental matter relate separate environmental issue number country nature amount timing outflow difficult predict december significant provision discount time value money material effect increase discount rate high discount unwind result decrease provision significant provision relate site nutley new jersey divest september estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago estimate remediation cost manufacturing site clarecastle ireland shut meantime environmental provision decrease chf million net mainly utilisation effect high discount rate net environmental expense chf million net expense chf million mainly increase provision follow reassessment expect cost environmental remediation clarecastle site matter group procedure environmental protection include annual report page include action take group regard climate change notably group commitment reduce greenhouse gas emission restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter pharmaceutical division significant provision relate business transformation initiative include resource flexibility plan site development plan baselkaiseraugst site redesign strategic realignment manufacturing network diagnostic division significant provision associate programme address longterm strategy corporate relate initiative outsourcing function share service centre external provider detail give note contingent consideration provision group party certain contingent consideration arrangement arise business combination significant non current provision discount average discount rate time value money material additional detail measurement total potential payment arrangement provide note finance report note roche group consolidate financial statement roche group provision provision relate item show table exception employee provision time cash outflow nature uncertain provision million chf sale return employee provision item total provision contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter inlicense alliance arrangement intangible asset purchase agreement include asset acquisition order gain access potential new product utilise company help develop group potential new product arrangement purchase agreement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment potential payment year give note roche group note roche group consolidated financial statement finance report legal case december legal provision include provision legal case chf million chf million mainly relate legal case pharmaceutical division chf million chf million diagnostic division chf million chf million provision record case settled mainly relate meso diagnostic legal case pharmaceutical legal matter list avastinlucentis investigation february italian antitrust authority agcm announce investigation determine roche genentech novartis enter agreement restrict competition italian market drug reference particular avastin market roche lucentis market novartis avastin lucentis different drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche eur million novartis eur million roche appeal agcm verdict tribunale amministrativo regionale del lazio tar december tar uphold decision agcm roche appeal verdict tar consiglio di stato july roche pay eur million fine protest avoid additional penalty fee record expense general administration january european court justice render decision question refer european court justice consiglio di stato july consiglio di stato issue final verdict case uphold verdict agcm tar roche file appeal corte suprema di cassazione reject october addition roche file motion revocation consiglio di stato pende hearing place april italian ministry health italian region notify group intention seek damage relate matter january french competition authority fca issue statement objection roche genentech novartis anticompetitive practice concern commercialisation avastin lucentis france fca allege roche genentech novartis abuse collective dominant position french market treatment wet agerelate macular degeneration september fca issue decision find roche genentech novartis infringe competition law impose fine eur million roche genentech roche genentech appeal decision february hear paris court appeal ruling expect issue february december liability hold fine include account payable line item payable note january fine pay protest avoid additional penalty fee september roche receive administrative fine letter turkish competition authority tca investigation tca allege roche novartis enter cartel aim prevent offlabel application avastin order foster onlabel application lucentis october fine turkish lira million pay protest avoid additional penalty fee roche file appeal decision addition group challenge policy regulation allow offlabelunlicense use reimbursement economic reason country group vigorously defend matter outcome matter determined time average wholesale price litigation hoffmannla roche inc hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey september case dismiss follow settlement matter conclude boniva litigation hoffmannla roche inc hlr genentech roche affiliate collectively roche name defendant numerous legal action dismiss case canada relate post menopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determined timefinance report note roche group consolidate financial statement roche group meso litigation february roche diagnostic corporation roche file lawsuit district court district delaware meso scale diagnostic llc meso patent infringement case involve certain patent own bioveris corporation bioveris company acquire group meso hold limited exclusive licence use certain aspect electrochemiluminescence ecl detection technology roche meso disagree scope licence lawsuit seek declaratory judgment judicial clarification roche infringe mesos licence november jury find roche use patent infringe scope meso licence injunction grant jury award meso usd million damage posttrial motion file party meso move enhancement prejudgment interest postjudgment royalty court hearing take place december district court issue final order judgment jury award confirm meso request enhance damage deny group appeal decision april court appeal issue rule reverse induce infringement decision vacate damage award court appeal affirm roche directly infringe patent vacate district court decision december noninfringement patent case remand district court new damage trial ongoing group vigorously defend matter addition pharmaceutical legal case list currently provision record potential future obligation confirm occurrence nonoccurrence uncertain future event obligation measure sufficient reliability hemlibra litigation baxalta inc baxalta gmbh baxalta subsidiary takeda pharmaceutical company limit file patent infringement declaratory judgment patent infringement suit district court district delaware allege genentech chugai pharmaceutical co ltd chugai currently imminently manufacture use sell offer sale import hemlibra infringe baxalta patent baxalta seek judgment infringement injunctive monetary relief attorney fee cost expense genentech serve complaint genentech response counterclaim complaint file june june chugai waive service september chugai file motion dismiss complaint lack personal jurisdiction december baxalta file request preliminary injunction genentech inhibitor patient subject injunction hearing hold district court district delaware june hearing baxalta withdraw request preliminary injunction inhibitor patient june baxalta submit new propose preliminary injunction order genentech permit sell hemlibra inhibitor patient noninhibitor patient currently hemlibra clinical trial select noninhibitor patient additional medically diagnose condition render factor viii therapy impracticable august district court rule baxalta deny request injunction september chugai dismiss case february district court issue final judgment favour genentech state hemlibra infringe baxalta patent base court definition key term relate patent february baxalta appeal decision august appeal court reverse claim construction rule district court favour genentech remand case district court september genentech file motion summary judgment multiple ground november district court hear genentech motion summary judgment invalidity noninfringement doctrine equivalence wilful infringement january district court grant genentech motion summary judgment enablement mean previously schedule trial cancel baxalta appeal rule decision expect group vigorously defend matter outcome matter determine time iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device company name defendant complaint file federal district court district columbia behalf service member relative allege kill injure iraq iraq lawsuit complaint allege defendant violate antiterrorism act state law provide fund terrorist organisation sale practice pursuant pharmaceutical andor medical device contract iraqi ministry health addition fhlr receive inquiry july department justice connection anticorruption investigation relate activity iraq include interaction iraqi government certain matter allege iraq lawsuit october department justice close inquiry fhlr july federal district court grant defendant motion dismiss plaintiff appeal decision january court appeals district columbia circuit reverse decision federal district court remand case proceeding defendant file petition rehear en banc court appeal district columbia circuit remain pende group vigorously defend matter outcome matter determine time roche group note roche group consolidated financial statement finance report tamiflu qui tam litigation roche holding ltd roche hold hoffmannla roche inc hlr genentech inc genentech serve lawsuit file relator district court district maryland qui tam whistleblower provision false claim act lawsuit originally file seal year early behalf government state government lawsuit allege certain improper conduct group respect sale tamiflu government state government department justice decline intervene lawsuit january group file motion dismiss september plaintiff dismiss complaint roche hold genentech district court deny hlrs motion summary judgment november department justice file motion dismiss claim motion stay pende decision supreme court relate matter group vigorously defend matter outcome matter determined time novartis litigation relate cabilly royalty novartis vaccine diagnostics inc novartis pharma ag collectively novartis file lawsuit genentech inc genentech california state court san mateo county novartis allege mistakenly overpay entitle return certain cabilly royalty product cosentyx ilaris total usd million follow expiry cabilly patent genentech novartis discussion cabilly royalty owe cosentyx ilaris manufacture import prior patent expiry sell patent expiry june genentech file notice removal seek case state court federal court july genentech file motion dismiss claim ground response genentech motion novartis file amend complaint august september genentech file motion dismiss amend complaint similar ground february novartis genentech engage voluntary mediation result settlement outcome october case management conference court unilaterally decide recalendar oral argument genentech motion dismiss hear february group vigorously defend matter outcome matter determine time herceptin investigation february south african competition commission commission file referral competition tribunal prosecution roche holding ltd f hoffmannla roche ltd roche products pty ltd roche allege excessive pricing trastuzumab herceptin contravention south african competition act commission referral affidavit allege excessive price herceptin constitute violation basic human right include right access healthcare enshrine south africa bill rights deny access life save medicine woman live breast cancer allege excessive pricing herceptin roche take place january november south african private healthcare sector south african public healthcare sector period november july commission ask competition tribunal impose penalty roche october roche submit reply competition tribunal group vigorously defend matter outcome matter determined time university pennsylvania litigation january university pennsylvania file patent litigation action genentech inc genentech base claim herceptin perjeta phesgo herceptin hylecta infringe patent patent accord complaint patent generally relate method treat erbb proteinmediated cancer tumour administer compound inhibit formation erbb follow radiation genentech file partial motion dismiss university pennsylvanias claim wilfulness march grant december jury trial schedule september group vigorously defend matter outcome matter determined timefinance report note roche group consolidate financial statement roche group debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt change finance cash flow net gain loss redemption repurchase bond note amortisation debt discount financing cost business combination asset acquisition net foreign currency transaction gain loss currency translation effect change foreign exchange rate change fair value hedge instrument change december bond note commercial paper amount bank financial institution borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche group note roche group consolidated financial statement finance report bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollar note fix rate note september principal usd billion isin usbb note january principal usd billion isin usbm note september principal usd billion outstanding usd billion isin usbn note march principal usd billion isin usbq note march principal usd billion isin usbu na note september principal usd billion outstanding usd billion isin usbe na note march principal usd billion isin usbt na note november principal usd billion outstanding usd billion isin usbj na note march principal usd billion isin usbs note principal usd billion isin usbk na note january principal usd billion isin usbl na note march principal usd billion isin usbv na note september principal usd billion isin usbp na note december principal usd billion isin usbw na note december principal usd billion isin usbx note march principal usd billion outstanding usd billion isin usuan usau note november principal usd billion isin usbh na note december principal usd billion isin usby dollar note float rate note september principal usd billion isin usbz na note march principal usd billion isin usbr na note march principal usd billion isin usca na euro medium term note programme fix rate note march principal eur billion isin xs note february principal eur billion isin xs note august principal gbp billion outstanding gbp billion isin xs na note february principal eur billion isin xs swiss franc bond fix rate bond september principal chf billion isin ch bond november principal chf billion isin ch na bond september principal chf billion isin ch bond september principal chf billion isin ch bond june principal chf billion isin ch na bond february principal chf billion isin ch na bond march principal chf billion isin ch na bond september principal chf billion isin ch na bond february principal chf billion isin ch na bond september principal chf billion isin ch na bond february principal chf billion isin ch na finance report note roche group consolidate financial statement roche group recognise liability effective interest rate bond note millions chf continue effective interest rate underlie include instrument hedging genentech senior note senior note july principal usd billion outstanding usd billion isin usac na total bond note bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond total unamortised discount issuance bond note february group complete offer chf billion fix rate bond issue tranche chf billion bond zero coupon chf billion bond coupon chf billion bond coupon chf billion bond coupon zero coupon fix rate bond principal chf billion mature november bond mature february february february respectively bond list swiss exchange group receive chf million aggregate net proceed issuance sale fix rate bond march group complete offer usd billion fix rate note coupon usd billion fix rate note coupon usd billion fix rate note coupon note mature march march march respectively group receive chf million aggregate net proceed issuance sale fix rate note march group complete offer usd billion float rate note rate equal secure overnight financing rate sofr plus margin usd billion float rate note rate equal sofr plus margin note mature september march respectively group receive chf million aggregate net proceed issuance sale float rate note september group complete offer chf billion fix rate bond issue tranche chf billion bond coupon chf billion bond coupon bond mature june september respectively bond list swiss exchange group receive chf million aggregate net proceed issuance sale fix rate bond roche group note roche group consolidated financial statement finance report issuance bond note march group complete offer usd billion usd billion fix rate note coupon respectively note mature march march respectively group receive chf million aggregate net proceed issuance sale fix rate note march group complete offer usd billion float rate note rate equal secure overnight financing rate sofr plus margin note mature march group receive chf million aggregate net proceed issuance sale float rate note december group complete offer usd billion fix rate note coupon usd billion fix rate note coupon usd billion fix rate note coupon note mature december december december respectively group receive chf million aggregate net proceed issuance sale fix rate note redemption repurchase bond note date september group redeem fix rate bond principal chf billion cash outflow chf million plus accrue interest effective interest rate bond date november group redeem zero coupon fix rate bond principal chf billion cash outflow chf million effective interest rate bond redemption repurchase bond note date march group redeem notes outstanding eur billion effective interest rate note cash outflow chf million gain loss record redemption july group resolve exercise option early redemption fix rate note outstanding usd billion par month schedule date september cash outflow chf million plus accrue interest gain loss record redemption effective interest rate note december group resolve exercise option early redemption fix rate note outstanding usd billion par month schedule date january cash outflow chf million plus accrue interest gain loss record redemption effective interest rate note cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf dollar note swiss franc bond total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf euro medium term note programme euro note dollar note swiss franc bond total cash outflow redemption repurchase bond note finance report note roche group consolidate financial statement roche group commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue usd billion unsecured commercial paper note guarantee roche holding ltd commit credit line available backstop support commercial paper program usd billion december usd billion july previously exist committed credit line refinance new committed credit line initial maturity year annual extension option exercise extend maturity maturity note program exceed day date issuance december unsecured commercial paper note principal usd billion usd billion average interest rate outstanding movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution december amount outstanding chf million chf million year amount denominate currency average interest rate position notably include bridge loan facility draw december finance share repurchase transaction note bridge loan facility fully repay partly proceed new debt issuance partly internal cash generation december bridge loan facility outstanding chf billion roche group note roche group consolidated financial statement finance report equity attributable roche shareholder change equity attributable roche shareholder millions chf share retain fair value hedge translation c apital earning reserve reserve reserve total year end december january b net income recognise income statement financial asset fair value oci fair value gain loss equity investment fair value oci fair value gain loss take retain earning disposal equity investment fair value oci fair value gain loss debt security fair value oci fair value gain loss transfer income statement debt security fair value oci income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend share repurchase equity compensation plan net transaction equity change noncontrolle interest december c entire transfer income statement report financial income expense b cost hedging reserve relate eurusd crosscurrency swap include hedging reserve january amount chf million net tax c remain crosscurrency swap expire march note hedge reserve long include cost hedge instrument december finance report note roche group consolidate financial statement roche group change equity attributable roche shareholder millions chf share retain fair value hedge translation c apital earning reserve reserve reserve total year end december january net income recognise income statement financial asset fair value oci fair value gain loss equity investment fair value oci fair value gain loss take retain earning disposal equity investment fair value oci fair value gain loss debt security fair value oci fair value gain loss transfer income statement debt security fair value oci income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend share capital reduction equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financing cost note relate fair value loss treasury lock designate cash flow hedge roche group note roche group consolidated financial statement finance report share repurchase share capital reduction november extraordinary general meeting roche shareholder approve reduction share capital roche holding ltd group parent company chf million chf million chf million cancellation share repurchase novartis december roche group repurchase million roche share hold novartis total consideration chf billion repurchased share report treasury share december share cancel february necessary legal procedure complete cancellation share share capital roche holding ltd decrease chf million chf million chf million reduction share capital effective begin february entry share capital reduction commercial register canton baselstadt february publication share capital reduction swiss official gazette commerce february chf billion credit facility bank draw finance share repurchase fully repay partly proceed new debt issuance partly internal cash generation note share capital follow share capital reduction describe december authorise issue share capital roche holding ltd group parent company consist share nominal value chf december share thereof share hold group treasury share cancel february share bearer share group maintain register shareholder december base information supply group shareholder group pool voting right own share represent issue share december share represent issue share exclude treasury share hold group cancel february voting power figure include share pooled voting right hold outside group individual member group december shareholder group announce continue shareholder pooling agreement exist modify shareholder composition duration pool extend indefinite period december base information supply group ms maja oeri member pool hold share independently pool represent issue share december share represent issue share exclude treasury share hold group cancel february voting power describe note nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle time exchange share participation certificate nonvoting equity security consent bearer thereof dividend march shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity security total chf million chf million record retain earning board director propose dividend business year chf share nonvoting equity security dividend proposal subject approval annual general meeting march approve result total distribution shareholder chf millionfinance report note roche group consolidate financial statement roche group equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security total equity instrument record equity original purchase cost december fair value share chf million chf million fair value nonvoting equity security chf billion chf billion equity instrument hold group potential conversion obligation arise group equity compensation plan note addition describe million repurchase share report treasury share december cancel february reserve fair value reserve december fair value reserve represent cumulative net change fair value financial asset fair value oci asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc roche group note roche group consolidated financial statement finance report subsidiary associate chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total chf million chf million record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december partially revise july roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose occur chugai guarantee roche right maintain shareholde percentage chugai allow roche exercise preemptive right rightsfinance report note roche group consolidate financial statement roche group licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement exclude japan south korea sign revise amend restate rest world umbrella right agreement exclude japan south korea taiwan sign august agreement chugai shall offer roche right refusal development marketing chugais development compound market outside japan exclude south korea taiwan agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area smallmolecule synthetic drug research biotechnologybase drug discovery associate december group acquire interest freenome holdings inc freenome privately own company base south san francisco california december group interest freenome december investment assess treat associate group group account freenome equity method base freenomes financial statement available group carry value group share freenome net asset asset chf million december chf million include noncurrent asset note group share freenomes result loss chf million nil include financial income expense note roche group note roche group consolidated financial statement finance report noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement equity investment fair value oci debt security fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income business combination dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change noncontrolle interest december chugai noncontrolle interest total noncontrolle interest employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefitsfinance report note roche group consolidate financial statement roche group pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group long term financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan chf million chf million asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan roche k saving plan define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation prepare accordance requirement ias use group financial statement group major pension plan locate switzerland germany total account group define benefit obligation pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contribution base certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility pension plan group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic contribution plan underfunding normally remedie additional company contribution contribution group pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit unfunded plan contribution base minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan roche group note roche group consolidated financial statement finance report pension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai additional voluntary contribution jpy billion pension plan jpy billion chugai plan fully describe chugais ifrs financial statement uk pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan postemployment benefit opeb plan represent approximately group define benefit obligation consist postemployment healthcare life insurance scheme mainly plan mainly unfunde andor contributory employee group reimburse retire employee directly financial resource group major opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient contribution usd million group plan december ifrs funding status include reimbursement right fund opeb plan define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement funding status fund group define benefit plan responsibility respective senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level unfunded plan mainly group german affiliate fully reserve pension obligation selffinance local affiliate operation ifrs funding status fund define benefit plan increase reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act finance report note roche group consolidate financial statement roche group define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liability plan asset responsibility investment strategy fund plan respective senior governance body board trustee assetliability study perform regularly major pension plan study examine obligation postemployment benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset loss chf million gain chf million exclude actual return reimbursement right recognition plan asset limit present value economic benefit available refund plan reduction future contribution plan limit asset recognition arise result surplus base current market assumption certain swiss pension plan recognisable ifrs adjustment arise limit recognition asset define benefit plan record comprehensive income equity adjustment chf million chf million roche group note roche group consolidated financial statement finance report define benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january interest income plan asset reimbursement right remeasurement plan asset reimbursement right currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement administration cost december define benefit plan limit asset recognition millions chf limit asset recognition january movement record comprehensive income december fair value plan asset december exclude limit asset recognition limit asset recognition include limit asset recognition define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property primarily private commercial property fund mainly observable input level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity insurance contract risk management purpose mainly observable input level fair value hierarchy unobservable input level fair value hierarchy include fair value plan asset group share nonvoting security fair value chf million chf million debt instrument issue group fair value chf million chf millionfinance report note roche group consolidate financial statement roche group define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee uk join group define contribution plan new employee germany join contributionbase plan minimum guarantee result proportion define benefit obligation relate closed plan expect decrease future define benefit pension plan switzerland final benefit contribution base minimum guarantee remain open new employee define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year roche group note roche group consolidated financial statement finance report actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide post employment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour average life expectancy assume individual age follow define benefit plan average life expectancy age major scheme year male female country mortality table switzerland bvg projected cmi model united states pri project mp germany heubeck table g project cmi model mortality assumption pension plan switzerland base bvg bvg apply continuous mortality investigation cmi model longterm rate longevity improvement group mortality assumption pension plan germany heubeck table g apply cmi model longterm rate longevity improvement financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase take account expect inflation rate factor expect rate pension increase generally link expected inflation rate funding status plan expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development usfinance report note roche group consolidate financial statement roche group sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation define benefit plan sensitivity define benefit obligation actuarial assumption millions chf increase decrease define benefit obligation life expectancy year increase discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately chf million additional voluntary contribution plan benefit pay unfunded plan estimate approximately chf million relate german define benefit plan roche group note roche group consolidated financial statement finance report equity compensation plan group operate equity compensation plan include separate plan chugai ifrs sharebase payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche connect roche option plan bonus stock award chugai plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai plan exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note finance report note roche group consolidate financial statement roche group equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date roche ssar plan million ssar available issuance tenyear period roche ssar plan renew effective january million ssar available issuance tenyear period start right nontradable equitysettle award tenyear duration vest phase basis year right grant sevenyear duration vest phase basis year provision renew roche ssar plan consistent term applicable california security law meaning section title california corporations code section title california code regulation approval annual financial statement constitute approval roche ssar plan describe annual financial statement majority roche hold ltds outstanding security entitle vote roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable weighted average remain weight average weight average number outstanding contractual life exercise price number exercisable exercise price year grant thousand year chf thousand chf total roche group note roche group consolidated financial statement finance report roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity security rsus vest phase basis year subject performance condition rsus grant vested threeyear period currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan renew effective january million nonvoting equity security available issuance tenyear period start roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant provision renew roche rsu plan consistent term applicable california security law meaning section title california corporations code section title california code regulation approval annual financial statement constitute approval roche rsu plan describe annual financial statement majority roche hold ltds outstanding security entitle vote roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche connect programme enable employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan chf million chf million roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date option non tradable equitysettle award tenyear duration vest phase basis year option grant sevenyear duration vest phase basis year roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable finance report note roche group consolidate financial statement roche group roche option plan term option outstanding december option outstanding option exercisable weight average remain weight average weight average number outstanding c ontractual life exercise price number exercisable exercise price year grant thousand year chf thousand chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year subject approval annual general meeting march issue march number award fair value award calculate grant date fair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche roche stocksettle stock restrict stock roche appreciation right unit plan option plan progressively progressively progressively vest period year year year contractual life year na year number grant year thousand weight average fair value chf model binomial market price binomial input option pricing model share price grant date chf exercise price chf expect volatility b na expect dividend yield na early exercise factor c na expect exit rate na fair value roche rsus equivalent share price date grant b volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream c early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour roche group note roche group consolidated financial statement finance report lease group lessee group enter lease transaction lessee mainly reason convenience flexibility group good cash generation ability enjoy strong longterm investment grade credit rating typically enter leasing arrangement finance consideration main area lease group enter property office apartment small number lease represent value car sale representative office equipment photocopier similar rightofuse asset report group lease show table rightofuse asset movement carry value asset millions chf building land machinery land improvement equipment total year end december january business combination addition disposal depreciation impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination addition disposal depreciation impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value finance report note roche group consolidate financial statement roche group classification impairment reversal charge rightofuse asset millions chf cost sale marketing distribution research development general administration total impairment reversal charge impairment charge rightofuse asset mainly relate global restructuring plan note office closure liability report group lease show table lease movement carry value recognise liability millions chf january increase new lease arrangement repayment lease liability business combination asset acquisition disposal interest expense lease liability currency translation effect december noncurrent lease liability current lease liability total lease liability maturity analysis lease liability give note liquidity risk section shortterm lease lease lowvalue asset account recognition exemption permit ifrs expense shortterm lease recognise straightline basis mainly include shortterm property lease employee apartment report chf million chf million expense lease low value asset recognise straightline basis mainly include certain office equipment report chf million chf million expense variable lease payment include measurement lease liability chf million chf million income subleasing rightofuse asset chf million income group enter sale leaseback transaction major cash flow respect lease group lessee show table lease cash flow millions chf include cash flow operating activity include cash flow financing activity total lease payment cash flow operating activity include cash flow shortterm lease lease lowvalue asset variable lease payment cash flow financing activity include payment interest principal portion lease liability prepayment lease commencement date roche group note roche group consolidated financial statement finance report lease commit commence july foundation medicine inc fmi enter bind lease agreement party lease laboratory office space building boston construct landlord location currently know boston seaport accord agreement fmi commit lease building year commencement date lease currently expect second half commit future cash outflow relate agreement estimate approximately usd million base current assumption november genentech inc genentech enter bind lease agreement party lease laboratory office space building south san francisco construct landlord location currently know gateway accord agreement genentech commit lease building seven year commencement date lease currently expect half commit future cash outflow relate agreement estimate approximately usd million base current assumption group lessor diagnostic division group enter certain contract include placement diagnostic instrument supply reagent consumable service arrangement depend term agreement instrument placement result finance lease operating lease group perform thorough customer assessment new leasing agreement sign usually group retain right terminate modify contract certain condition meet finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease income finance lease recognise revenue amount represent fair value instrument approximate present value minimum lease payment arrangement finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest method record royalty operating income follow amount record income respect finance lease finance lease select item income million chf sell profit difference sale cost sale finance income net investment lease currently group income variable lease payment finance lease carry net investment finance lease report receivables chf million chf million finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt year year year year year year total unearned finance income na na unguaranteed residual value na na net investment lease finance report note roche group consolidate financial statement roche group operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement income operating lease recognise revenue straightline basis lease term lease revenue entirely base variable lease payment subject subsequent reagent sale performance obligation reagent satisfied lease income chf million chf million include sale chf million chf million relate variable lease payment depend index rate lease asset report property plant equipment show table machinery equipment subject operating lease movement carry value asset millions chf lease use total lease use total january cost accumulate depreciation impairment net book value year end december january business combination asset acquisition addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value undiscounte amount expect receive noncancellable operating lease show table operating lease future minimum lease receipt noncancellable lease millions chf year year year year year year total minimum receipt roche group note roche group consolidated financial statement finance report earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million weight average number outstanding share million number outstanding nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number outstanding share nonvoting equity security calculate basic earning share millions basic earning share nonvoting equity security chf dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number outstanding share nonvoting equity security millions adjustment assume exercise equity compensation plan dilutive million weight average number outstanding share nonvoting equity security calculate diluted earning share millions diluted earning share nonvoting equity security chf finance report note roche group consolidate financial statement roche group statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic division calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown inventory fair value adjustment net gain loss disposal product adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest receive pay dividend receive marketable security investment millions chf interest receive pay dividend receive total roche group note roche group consolidated financial statement finance report cash flow financing activity cash flow financing activity primarily proceed issuance repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include cash flow indicate group transaction provider equity debt financing cash flow lease payment include financing activity cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche shareholder dividend noncontrolle shareholder chugai noncontrolle interest dividend withholding tax total liability arise financing activity movement carry value recognise asset liability millions chf cash principal derivative collateral p ortion financial receivables interest lease instrument payable debt p ayable l iabilitie net net total year end december january cash flow outflow inflow noncash change finance cost business combination asset acquisition fair value foreign exchange rate december year end december january cash flow outflow inflow noncash change finance cost business combination asset acquisition fair value foreign exchange rate december significant noncash transaction significant noncash transaction leasing transaction group lessee note finance report note roche group consolidate financial statement roche group risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral longterm forecasting controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset group consider financial asset default counterparty unlikely pay obligation group assess counterparty default group consider qualitative quantitative indicator eg overdue status base datum develop internally certain financial asset obtain external source major group receivables past day relate public customer risk default public customer consider low group reasonable supportable information demonstrate lag default criterion appropriate particular customer segment account receivable december group trade receivables chf billion chf billion subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount group use allowance matrix estimate allowance doubtful account trade receivable expect credit loss ecl rate base group historical experience group expectation economic condition period receivables expect pay roche group note roche group consolidated financial statement finance report customer credit risk exposure base account receivable day overdue millions chf overdue overdue overdue credit total current month month year impair december gross carrying group expect credit loss rate allowance doubtful account december gross carrying group expect credit loss rate allowance doubtful account december group combine trade receivable balance national wholesale distributor mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion represent group consolidated trade receivables chf billion represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral consider measure expect credit loss trade receivable nature geographic location counterpartie account receivable overdue impair show table include balance national wholesaler describe account receivable overdue net allowance doubtful account allowance nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total cash marketable security exclude equity security december group cash marketable security exclude equity security chf billion chf billion subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly cash cash equivalent hold bank financial institution predominantly rate investment grade base moodys standard poor rating cash shortterm time deposit subject rule limit group exposure individual financial institutionsfinance report note roche group consolidate financial statement roche group impairment cash cash equivalent measure month expect credit loss ecl basis reference external credit rating counterpartie reflect short maturity exposure cash cash equivalent group consider cash cash equivalent low credit risk base external credit rating investment marketable security exclude equity security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity counterpartie credit rating baa moodys bbb standard poor credit risk counterpartie external rating investment grade rating closely monitor review individual basis rating analysis cash marketable security exclude equity security market value millions chf fair value fair value oci amortise cost oci amortise cost total month ecl month ecl total month ecl month ecl aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amount loss allowance loss allowance relate fair value oci affect carry marketable security exclude equity security book correspond oci reserve instead debt security amortise cost fair value oci investment grade consider low risk impairment allowance determine month expect credit loss ecl reference external credit rating counterpartie debt security group observe significant increase credit risk require application lifetime expect credit loss impairment model addition material movement loss allowance respectively master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment losse financial asset exclude equity investmentssecuritie impairment loss roche group note roche group consolidated financial statement finance report liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total chf billion chf billion chf billion chf billion serve backstop line commercial paper program july previously exist committed credit line refinance new committed credit line initial maturity year annual extension option exercise extend maturity remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carrying value total year year year year december debt bond note debt contingent consideration account payable noncurrent liability lease liability current liability lease liability derivative financial instrument total financial liability december debt bond note debt contingent consideration account payable noncurrent liability lease liability current liability lease liability derivative financial instrument total financial liability takeorpay commitments group enter contract manufacturing agreement company develop manufacturing capacity flexibility mainly pharmaceutical division future minimum orpay commitment agreement total potential commitment group chf billion december chf billion commitment capital call group hold investment fund report debt investment fair value profit loss commit invest future capital call december total uncalled capital commitment group investment fund amount chf millionfinance report note roche group consolidate financial statement roche group market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equity valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread market risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component increase bond issuance february march september foreign exchange component price component remain largely stable foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro group foreign exchange risk management strategy preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option cross currency swap hedge transaction exposure application instrument intends continuously immunise unfavourable development foreign exchange rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc euro float rate financial instrument shortterm debt group interest rate risk management strategy optimise net interest result group use forward contract option interest rate swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure roche group note roche group consolidated financial statement finance report price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment capital management group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group net equity significantly impact share repurchase note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine chugai managementfinance report note roche group consolidate financial statement roche group financial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument millions chf financial instrument mandatorily financial financial fair value instrument fair value asset total profit fair value hedging amortise financial carrying loss oci instrument cost l iabilitie value fair value december noncurrent asset equity debt investment financial noncurrent asset account receivable marketable security equity security debt security money market instrument time account month cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable noncurrent liability current liability total financial liability roche group note roche group consolidated financial statement finance report carry value fair value financial instrument millions chf financial instrument mandatorily financial financial fair value instrument fair value asset total profit fair value hedging amortise financial carrying loss oci instrument cost l iabilitie value fair value december noncurrent asset equity debt investment financial noncurrent asset account receivable marketable security equity security debt security money market instrument time account month cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable noncurrent liability current liability total financial liability fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity periodsfinance report note roche group consolidate financial statement roche group fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total december marketable security equity security fair value profit loss debt security fair value oci debt security fair value profit loss money market instrument fair value oci derivative financial instrument equity investment fair value oci equity debt investment fair value profit loss financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value december marketable security equity security fair value profit loss debt security fair value oci debt security fair value profit loss money market instrument fair value oci derivative financial instrument equity investment fair value oci equity debt investment fair value profit loss financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date equity debt investment fair value oci fair value profit loss base valuation model use recently publish observable market datum group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year roche group note roche group consolidated financial statement finance report level fair value detail determination level fair value measurement set contingent consideration arrangement millions chf january arise business combination utilise settlement total gain loss include income statement unused amount reverse record general administration additional create record general administration discount unwind include financing cost total gain loss include comprehensive income currency translation effect december contingent consideration arrangement group party certain contingent consideration arrangement include business combination fair value contingent consideration business combination determine consider expect payment payment expect month discount present value riskadjusted average discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate higher riskadjuste discount rate low december total potential payment contingent consideration arrangement arise business combination chf billion chf billion follow potential payment contingent consideration arrangement millions chf acquisition year acquire operating segment dutalys roche pharmaceutical genia diagnostic diagnostic december finance report note roche group consolidate financial statement roche group derivative financial instrument cash collateral agreement place counterpartie certain derivative financial instrument mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net collateral arrangement movements cash collateral receivable accrue liability millions chf january net cash deliver group fair value currency translation effect december roche group note roche group consolidated financial statement finance report hedge accounting describe group risk management strategy hedge transaction exposure arise foreign currency flow monetary position hold foreign currency generate appropriate mix fix float rate exposure level hedging depend market condition business requirement group group designate specific interest rate risk management objective ensure predetermine level interest rate risk exposure float rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment report date ensure economic relationship exist hedge item hedging instrument group perform qualitative assessment hedge effectiveness critical term match method critical term hedge item hedge instrument match group conclude risk hedge hedged item hedge instrument sufficiently align inherent mismatch hedge relationship hedge ratio apply actual quantity hedge hedge accounting accounting treatment source ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential source ineffectiveness assessment method interest rate andor foreign exchange rate cash flow hedge counterparty credit risk critical term match fluctuation foreign exchange rate fluctuation cash flow hedge low volume hedge item critical term match counterparty credit risk interest rate fluctuation fair value hedge counterparty credit risk critical term match ineffective portion hedge accounting recognise income statement include financial income expense measure hypothetical derivative method cash flow hedge cumulative dollar offset method fair value hedge december potential source ineffectiveness individually collectively result material amount actual ineffectiveness report hedge accounting relationship table show fair value nominal amount derivative financial instrument include range maturity nominal hedge instrument designate hedge instrument cash flow hedge fair value hedge december respectively group follow cash flow hedge fair value hedge designate qualifying hedge relationship fair value nominal amount derivative hedge accounting december fair value asset fair value liability nominal million chf million chf maturity range cash flow hedge risk hedge interest rate foreign exchange rate fluctuation crosscurrency swap na risk hedged foreign exchange rate fluctuation forward exchange contract jpy billion risk hedge interest rate fluctuation treasury lock na total fair value hedge risk hedge interest rate fluctuation interest rate swap usd million interest rate swap eur million interest rate swap chf million total finance report note roche group consolidate financial statement roche group fair value nominal amount derivative hedge accounting december fair value asset fair value liability nominal million chf million chf maturity range cash flow hedge risk hedge interest rate foreign exchange rate fluctuation crosscurrency swap na risk hedged foreign exchange rate fluctuation forward exchange contract jpy billion risk hedge interest rate fluctuation treasury lock na total fair value hedge risk hedge interest rate fluctuation interest rate swap usd million interest rate swap eur million interest rate swap chf million total fair value derivative financial instrument hedge accounting include current asset note current liability note group approach manage market risk include interest rate risk foreign currency risk discuss market risk section note cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euro date march group redeem remain note outstanding eur billion note related remain cross currency swap expire time ineffective portion november december group enter treasury locks hedge interest rate risk fix rate note issue group december date treasury lock settle december relate hedging reserve chf million exclude income taxis chf million net tax hold deduction equity december chf million exclude income taxis chf million net tax release transfer income statement financing cost note redemption fix rate note ineffective portion chugai enter forward exchange contract hedge foreign translation exposure swiss franc dollar december instrument record fair value asset chf million fair value liability chf million fair value asset chf million fair value liability chf million ineffective portion roche group note roche group consolidated financial statement finance report carry item designate hedge item cash flow hedging relationship million chf asset liability asset liability december bond note risk hedge crosscurrency swap interest rate foreign exchange rate fluctuation bond note inventory risk hedge forward exchange contract foreign exchange rate fluctuation inventory hedge reserve continue hedge relationship millions chf cross forward cross forward treasury currency exchange treasury currency exchange total lock swap contract total lock swap contract january gain loss take equity transfer income statement income taxis noncontrolle interest currency translation effect december entire transfer income statement report financing cost financial income expense note date march group redeem remain note outstanding eur billion note related remain crosscurrency swap expire time result remain hedging reserve crosscurrency swap december hedging relationship hedge accounting long apply change hedge reserve equity show note expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow undiscounted cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturityfinance report note roche group consolidate financial statement roche group expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow fair value hedge group enter interest rate swap hedge exposure change fair value fixedterm debt instrument respect benchmark interest rate december instrument record fair value asset chf million fair value liability chf million fair value asset chf million fair value liability chf million fair value adjustment chf million record expense interest rate swap chf million expense fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group approach manage market risk include interest rate risk discuss market risk section note carry item designate hedge item fair value hedge relationship million chf fair value fair value adjustment adjustment liability cumulative current year december bond note risk hedged interest rate swap interest rate fluctuation bond note december bond note risk hedged interest rate swap interest rate fluctuation bond note net investment hedge group net investment hedge roche group note roche group consolidated financial statement finance report relate party control shareholder follow share capital reduction describe note december share capital roche holding ltd group parent company consist bearer share nominal value chf december bearer share december base information supply group shareholder group pool voting right own share represent issue share december share represent issue share exclude treasury share hold group cancel february voting power figure include share pooled voting right hold outside group individual member group december shareholder group announce continue shareholder pool agreement modify shareholder composition group consist mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement exist duration pool extend indefinite period december base information supply group ms maja oeri member pool hold share independently pool represent issue share december share represent issue share exclude treasury share hold group cancel february voting power mr andr hoffmann dr jrg duschmal member board director roche holding ltd mr hoffmann receive remuneration totalling chf chf dr duschmal receive remuneration totalling chf chf transaction group individual member shareholder group subsidiary associate list group subsidiary associate include note list exclude chugais subsidiary company material notably company inactive dormant liquidation transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associatesfinance report note roche group consolidate financial statement roche group key management personnel total remuneration key management personnel chf million chf million member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee chairman board director member corporate executive committee cec roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member cec members cec participate certain equity compensation plan describe term vest condition fair value award disclose note new member cec include table calendar year join cec similarly member cec retire partway year include calendar year leave cec remuneration member board director corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plans board fee employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include remuneration report disclose annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration member board director corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee annual report roche group note roche group consolidated financial statement finance report bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year subject approval annual general meeting march issue march number award fair value award calculate grant date equity compensation plan member corporate executive committee receive equity compensation show follow table number right option award grant member corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan contribution pay member corporate executive committee millions chf roche connect define benefit plan transaction group define benefit plan employee group describe note finance report note roche group consolidate financial statement roche group list subsidiary associate follow list group subsidiary associate excludes chugais subsidiary company material notably company inactive dormant liquidation list company share capital equity interest location company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million nonliste company share capital equity interest location company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial buenos aire ar roche diabetes care argentina sa buenos aire ars australia roche diabetes care australia pty limited north ryde aud roche diagnostic australia pty limited north ryde aud roche product pty limited sydney aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk usd belgium roche diagnostic belgium nv diegem eur roche sanv brussels eur bermuda chemical manufacturing trading company limit pembroke usd hoffmannla roche product limit pembroke usd roche capital services ltd pembroke rub roche catalyst investments ltd pembroke usd roche financial investments ltd pembroke usd roche financial management ltd pembroke usd roche financial services ltd pembroke usd roche international ltd pembroke usd roche intertrade limited pembroke usd roche operation ltd pembroke usd roche services holdings ltd pembroke usd bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp roche group note roche group consolidated financial statement finance report share capital equity interest location company city millions china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai ltd shanghai usd roche diagnostic suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop tib molbiol sas santiago de cali cop congo democratic republic roche drc sarlu kinshasa usd costa rica roche services america sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark obi aps hadsund dkk roche diagnostic copenhagen dkk roche innovation center copenhagen hoersholm dkk roche pharmaceutical copenhagen dkk dominican republic producto roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche diagnostic egypt trading sae giza egp roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp el salvador productos roche el salvador sa de cv antiguo cuscatlan usd estonia roche eesti tallinn eur finland roche diagnostic oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas montbonnotsaintmartin eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur timkl sas montbonnotsaintmartin eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlung gmbh grenzachwyhlen eur flatiron health gmbh cologne eur foundation medicine gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diabete care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostic automation solution gmbh ludwigsburg eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche real estate service mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur rox health gmbh berlin eur signature diagnostic gmbh potsdam eur tib molbiol syntheselabor gmbh berlin eur ghana roche product ghana limit accra ghs greece roche hellas sa marousi eur roche diagnostic hellas sa marousi eur guatemala producto roche guatemala sociedad annima guatemala city gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf finance report note roche group consolidate financial statement roche group share capital equity interest location company city million india roche diabete care india private limited mumbai inr roche diagnostic india private limited mumbai inr roche information solution india private limit pune inr roche product india private limited mumbai inr indonesia pt roche indonesia jakarta idr iran roche par co ltd tehran irr ireland inflazome limited dublin eur roche ireland limited clarecastle eur roche products ireland limited dublin eur spark therapeutics ireland limited dublin eur israel medingo ltd yokneam illit il roche pharmaceutical israel ltd hod hasharon il italy roche diabetes care italy spa monza eur roche diagnostic spa monza eur roche spa monza eur tib molbiol srl genoa eur japan flatiron health kk tokyo jpy roche dc japan k k tokyo jpy roche diagnostic kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes kuwait roche trading medicine equipment device medical supply spc kuwait city kwd latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd moka mur mexico producto roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherland roche diabete care nederland bv almere eur roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche product limited lagos ngn north macedonia roche makedonija dooel skopje eur norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab producto roche interamericana sa prisa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd paraguay roche diagnostic paraguay sa asuncin pyg peru producto roche qfsa lima pen roche farma peru sa lima pen philippine roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd romania roche romania srl buchar ron roche group note roche group consolidated financial statement finance report share capital equity interest location company city millions russian federation rochemoscow jsc moscow rub limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostic rus moscow rub saudi arabia roche diagnostic saudi arabia llc riyadh sar roche product saudi arabia llc jeddah sar serbia roche doo beograd belgrade rsd singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystem pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostic proprietary limited midrand zar roche product proprietary limited midrand zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostic sl sant cugat del valls eur roche farma sa madrid eur tib molbiol sl madrid eur sweden roche ab solna sek roche diagnostic scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabete care switzerland ltd rotkreuz chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd basel chf roche sapac ltd basel chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd trkiye infogenetik molekler bilgi hizmetleri anonim irketi istanbul try roche diagnostic turkey anonim irketi istanbul try roche mstahzarlari sanayi anonim irketi istanbul try ukraine roche ukraine llc kiev uah united arab emirate roche diabetes care middle east fzco dubai ae roche diagnostic middle east fzco dubai ae roche pharmaceutical middle east fzco dubai ae finance report note roche group consolidate financial statement roche group share capital equity interest location company city millions united kingdom flatiron health uk ltd st albans gbp inflazome uk limited welwyn garden city gbp intermune holding limit welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostic limited burgess hill gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp spark therapeutic uk ltd london gbp tmema limited welwyn garden city gbp tusk therapeutics limit welwyn garden city gbp united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd bina technologies inc pleasanton usd bioveris corporation indianapoli usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine inc cambridge usd freenome holdings inc south san francisco usd genentech usa inc south san francisco usd genentech inc south san francisco usd genmark diagnostic inc carlsbad usd genmark holdings inc carlsbad usd good therapeutics inc south san francisco usd hoffmannla roche inc little fall usd survive corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc south san francisco usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc south san francisco usd kapa biosystem inc wilmington usd lexent bio inc cambridge usd memory pharmaceutical corp little falls usd prescient design corp south san francisco usd promedior inc south san francisco usd protocol inc salt lake city usd roche diabete care inc indianapoli usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche diagnostic seattle inc seattle usd roche holdings inc south san francisco usd roche laboratory inc little fall usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequence solutions inc pleasanton usd roche tcrc inc little fall usd seragon pharmaceuticals inc south san francisco usd spark therapeutic international holdings inc philadelphia usd spark therapeutics inc philadelphia usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc santa clara usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche sa caracas vef vietnam roche pharma vietnam company limited ho chi minh city vnd roche vietnam company limit ho chi minh city usd share capital local currency unit roche group note roche group consolidated financial statement finance report significant accounting policy consolidation policy subsidiary company group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euro functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive incomefinance report note roche group consolidate financial statement roche group revenue sale revenue sale good supply product sale service render recorded sale sale recognise promise customer contract performance obligation satisfied transferring control promise good service customer control promise good service refer ability direct use obtain substantially remain benefit good service control usually transfer shipment delivery receipt good customer service render accordance delivery acceptance term agree customer good subject installation instrument sell diagnostic division sale generally recognise completion installation customer site customer acceptance sale recognise transaction price base consideration group expect receive exchange good service exclude amount collect behalf party value add taxis taxis directly link sale contract contain performance obligation transaction price allocate performance obligation base relative standalone selling price instrument diagnostic division sell good reagent consumable service single contract contract combine revenue recognition purpose sale recognise satisfaction performance obligation contract instrument sell cash instalment sale transaction available customer finance lease operating lease transaction finance lease arrangement group transfer substantially risk reward ownership customer treat finance lease arrangement income finance lease recognise revenue amount represent fair value instrument approximate present value minimum lease payment arrangement interest rate embed finance lease arrangement approximately market rate income finance lease comparable revenue outright sale finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest rate method record royalty operating income operating lease income operating lease recognise revenue straightline basis lease term lease revenue entirely variable subject subsequent reagent sale performance obligation deliver reagent satisfied sale net discount base estimate relate obligation include standalone selling price fair value require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise contract distributor sale recognise good physically transfer distributor consignment arrangement distributor act agent case sale recognise control good transfer endcustomer distributor commission present marketing distribution commission similar payment distributor act principal deduct sale payment exchange distinct service consideration receive group exchange good service fix variable variable consideration recognise consider highly probable significant revenue reversal occur underlie uncertainty relate variable consideration subsequently resolve common element variable consideration pharmaceutical division list government regulatory mandatory price reduction major element mandatory price reduction b drug discount program medicaid plan contractual price reduction include rebate chargeback result contractual agreement primarily volume base performance base cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return roche group note roche group consolidated financial statement finance report revenue product sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim related sale estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivables sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability provision sale return record balance sheet provision group recognise defer income contract liability consideration receive receivable group transfer promise good service customer defer income mainly relate remain performance obligation good free charge certain patient access similar programme reagent consumable service remain performance obligation partially unsatisfie longterm contract include defer income relate amount group expect receive good service transfer customer exist noncancellable enforceable contract mainly associate contract minimum purchase commitment related reagent consumable previously sell instrument monitor maintenance service contract original duration year group elect practical expedient disclose transaction price remain performance obligation end report period point time group expect recognise sale royalty operating income royalty operating income include royalty income income outlicense agreement income disposal product item royalty income earn licence recognise underlie sale record licensee income outlicense agreement typically arise receipt upfront milestone similar payment party grant licence product technologyrelate intellectual property ip outlicense agreement entered obligation include commitment conduct research latestage development regulatory approval comarkete manufacturing licence grant usually right use ip generally unique basis allocate revenue performance obligation make use residual approach upfront payment licensing fee usually recognise grant licence income shall defer performance obligation residual approach defer income release recognise revenue performance obligation satisfy milestone payment typically receive reach specific scientific milestone development milestone achieve certain annual sale milestone commercial milestone development milestone income recognise point time highly probable respective milestone event criterion achieve risk revenue reversal consider remote commercial milestone income accrue recognise revenue highly probable annual sale milestone reach period payment receive disposal product similar right recognise revenue transfer control right extent payment relate performance obligation portion defer residual approach recognise revenue activity manufacturing service render income profitshare agreement collaboration partner recognise underlie sale cost sale record collaboration partner include income service render usually group primary business activity extent revenue record sale recognise control transfer performance obligation satisfy cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare agreement report cost sale startup cost validation achievement normal production capacity expense incurredfinance report note roche group consolidate financial statement roche group research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase iv cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase include asset acquisition capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur postacquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follows recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost roche group note roche group consolidated financial statement finance report recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incurredfinance report note roche group consolidate financial statement roche group lease group lessee inception contract group assess contract contain lease contract contain lease contract convey right control use identify asset period time exchange consideration group recognise rightofuse asset correspond lease liability contract contain lease lease commencement date shortterm lease lease lowvalue asset payment shortterm lease lease lowvalue asset recognise expense straightline basis term respective lease lease liability initially measure present value future lease payment pay lease commencement date lease payment discount interest rate implicit lease readily determinable group incremental borrowing rate respective market lease payment include fix payment variable payment depend index rate know lease commencement date payment exercise extension purchase option group reasonably certain exercise lease liability subsequently measure amortise cost effective interest method remeasure correspond adjustment relate rightofuse asset change future lease payment follow contract renegotiation change index rate reassessment option rightofuse asset initially measure cost comprise initial lease liability adjust payment lease commencement date include initial direct cost incur expect cost obligation dismantle remove refurbish underlie asset incentive receive rightofuse asset depreciate straightline basis lease commencement date short lease term useful life underlie asset rightofuse asset assess impairment indication impairment group lessor certain asset mainly diagnostic instrument lease thirdparty customer finance operating lease arrangement transaction enter separate contract combine contract include reagent consumable service treatment leasing transaction mainly determine lease consider operating finance lease require judgement make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer case lease finance lease operating lease arrangement legal form lease convey right use asset cover judgemental assessment finance lease finance lease asset report receivables equal net investment lease income finance lease recognise revenue amount represent standalone selling price instrument approximate present value minimum lease payment arrangement minimum lease payment exclude variable lease payment contingent rent finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest method record royalty operating income operating lease income operating lease recognise revenue straightline basis lease term amount represent standalone selling price instrument approximate present value minimum lease payment arrangement minimum lease payment exclude variable lease payment contingent rent lease revenue entirely base variable lease payment subject subsequent reagent sale recognise performance obligation reagent satisfy sale net discount base estimate relate obligation include standalone selling price require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise merger acquisition business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense roche group note roche group consolidated financial statement finance report asset acquisition asset acquisition acquisition legal entity qualify business combination date acquisition group initially recognise individual identifiable asset acquire liability assume cost group date acquisition allocate individual identifiable asset liability basis relative fair value date acquisition subsequent consideration performancerelate development milestone recognise intangible asset specific milestone achieve recognition criterion meet transaction rise goodwill material directly attributable acquisitionrelated cost include cost acquire asset goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value commercial software development cost capitalise certain recognition criterion technical feasibility commercial viability meet available use intangible asset amortise straightline basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment rightofuse asset intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost disposal value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset review necessary future depreciationamortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost disposal value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss acquire business include cashgenerating unit permanently cease operate treat disposal business separately identifiable goodwill generate initial acquisition business factor goodwill entirely unrelated continue operation cashgenerating unit goodwill deem dispose fully impair describe note apply acquire product permanently cease generate economic benefit acquire technology permanently cease operate impairment testing methodology describe note finance report note roche group consolidate financial statement roche group inventory inventory state low cost net realisable value cost finish good work process intermediate include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense receivables include account receivable receivables carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance receivable represent right consideration unconditional exclude contract asset allowance doubtful account record expect credit loss term receivables estimate base specific indicator age customer balance specific credit circumstance group historical loss rate category customer adjust forwardlooke macroeconomic datum expense doubtful trade receivables recognise marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience receivable write partly reasonable expectation recovery receivable write group continue engage enforcement activity attempt recover receivable recovery recognise profit loss trade lease receivables group apply simplified approach prescribe ifrs requirespermit use lifetime expect loss provision initial recognition receivables group measure allowance doubtful account equal credit loss expect lifetime trade lease receivables cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisition provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available roche group note roche group consolidated financial statement finance report financial instrument group classify financial instrument follow measurement category disclose note amortise cost fair value oci fair value oci equity investment fair value profit loss include hedging instrument classification depend group business model manage financial asset contractual term cash flow group reclassifie debt security financial asset amortise cost business model manage asset change initial recognition group measure financial asset fair value plus case financial asset fair value profit loss transaction cost directly attributable acquisition financial asset transaction cost financial asset carry fair value profit loss expense profit loss amortise cost asset hold collection contractual cash flow cash flow represent solely payment principal interest measure amortise cost provision impairment gain loss debt security subsequently measure amortise cost hedge relationship recognise profit loss asset derecognise impair interest income financial asset include financial income effective interest rate method asset amortise cost mainly comprise account receivable cash cash equivalent time account month fair value comprehensive income fair value oci financial asset hold collection contractual cash flow sell financial asset asset cash flow represent solely payment principal interest initially record subsequently carry fair value change fair value record comprehensive income recognition impairment gain loss interest revenue foreign exchange gain loss recognise profit loss financial asset derecognise cumulative gain loss previously recognise oci reclassify equity profit loss interest income financial asset include financial income effective interest rate method fair value comprehensive income asset mainly comprise money market instrument debt security equity investment fair value comprehensive income fair value oci equity investment private biotechnology company keep group strategic alliance effort asset subsequently measure fair value dividend recognise financial income profit loss dividend clearly represent recovery cost investment net gain loss recognise oci include fair value reserve asset derecognise cumulative gain loss previously recognise oci reclassify equity fair value reserve retain earning profit loss fair value profit loss financial asset performance evaluate fair value basis gain loss financial asset subsequently measure fair value profit loss hedge relationship recognise profit loss present financial income expense period arise fair value profit loss asset mainly comprise equity investmentssecuritie debt investment contingent consideration liability initially record subsequently carry fair value change fair value record general administration operating result income statement fair value profit loss hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense financial liability nonderivative financial liability financial liability initially record fair value transaction cost subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate methodfinance report note roche group consolidate financial statement roche group derecognition financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire impairment financial asset group recognise loss allowance expect credit loss ecl financial asset measure amortise cost debt security measure fair value oci trade lease receivables group measure allowance doubtful account equal lifetime ecl debt security carry fair value oci debt security financial asset amortise cost determine low credit risk base external credit rating counterpartie group measure loss allowance equal month ecl group consider debt security low credit risk credit risk rating equivalent globally understand definition investment grade group consider baa moodys bbb standard poor credit risk debt security carry fair value oci debt security financial asset amortise cost increase significantly initial recognition group measure loss allowance equal lifetime ecl group assume credit risk instrument increase significantly day past financial asset write partially realistic prospect recovery generally case group determine customer asset source income generate sufficient cash flow repay amount subject writeoff financial asset write subject enforcement activity order comply group policy recovery amount hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition eligibility hedge hedge instrument formal designation documentation hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expense cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense roche group note roche group consolidated financial statement finance report taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future tax liability uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan change accounting policy group implement minor amendment exist standard interpretation material impact group overall result financial position future new revise standard group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position group assess new revise standard mandatory finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg ag audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa christoph franz alan hippe chairman board directors chief financial officer basel january roche group statutory auditor report finance report statutory auditor report general meeting roche holding ltd basel report audit consolidated financial statement opinion audit consolidated financial statement roche holding ltd subsidiary group comprise consolidated balance sheet december consolidated income statement consolidate statement comprehensive income consolidate statement change equity consolidate statement cash flow year end note consolidate financial statement include summary significant accounting policy opinion consolidated financial statement page true fair view consolidate financial position group december consolidated financial performance consolidated cash flow year end accordance international financial reporting standard ifrs comply swiss law basis opinion conduct audit accordance swiss law international standard auditing isa swiss standard audit sach responsibility provision standard describe auditor responsibility audit consolidated financial statement section report independent group accordance provision swiss law requirement swiss audit profession international ethic standard board accountant international code ethic professional accountant include international independence standard iesba code fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion key audit matter chargeback rebate sale return pharmaceutical business carrying value product intangible asset available use pharmaceutical division income tax uncertain tax position key audit matter matter professional judgement significance audit consolidated financial statement current period matter address context audit consolidated financial statement form opinion thereon provide separate opinion mattersfinance report statutory auditor report roche group chargeback rebate sale return pharmaceuticals business key audit matter response group pharmaceutical business make sale audit procedure include sample customer fall certain basis obtain management calculation accrue governmentmandate commercial contract purchase liability provision account receivable deduction reimbursement arrangement test accuracy calculation assess significant b drug discount program group appropriateness key input assumption provide right return customer certain estimate perform assessment reference product return period case extend internal external source information include year future arrangement result term applicable contract government pricing deduction gross amount invoice arrive sale information historical rate chargeback rebate create obligation group provide customer historical rate sale return consideration current credit chargeback rebate payment estimate trend amount deduct gross sale record accrue liability rebate allowance sale return evaluate accuracy management estimate deduction account receivable chargeback compare rate historical estimate rate estimate base analyse exist contractual actual rebate payment chargeback assess legislatively mandate obligation recent trend change accrual rate estimate historical experience compare accrual rate current chargeback rebate payment sale return trend management determine accrue liability deduction account receivable expect chargeback evaluate appropriateness group rebate predominantly contractual price reduction revenue recognition accounting policy include chf million necessary december recognition measurement deduction gross sale additionally provision sale return mainly relate relate chargeback rebate sale return product loss exclusivity chf million relate disclosure record december focus area arrangement complex establish appropriate yearend position require significant judgement estimation management assumption require estimate complicated give recent loss exclusivity group pharmaceutical product information chargeback rebate sale return pharmaceutical business refer following note significant accounting policy note general accounting principle key accounting judgement estimate assumption page note revenue note account receivable note current liability note provision contingent liability roche group statutory auditor report finance report carry value product intangible asset available use pharmaceutical division key audit matter response product intangible available use audit procedure include challenging pharmaceutical division chf million robustness key assumption determine represent inprocess research development asset recoverable amount include forecast revenue acquire business combination discount rate asset acquisition inlicense arrangement challenge base understanding inherent uncertainty research commercial prospect individual product development process intangible asset available relevant business area market use particularly risk impairment impairment operate valuation specialist assist assessment require management key assumption evaluate assumption methodology judgement clinical technical commercial management relation discount rate assess viability new product accordingly focus key input project pricing volume audit work area risk include inability product project share therapeutic area achieve successful trial result obtain require clinical compare relevant assumption industry forecast regulatory approval highly competitive business review analyst commentary compare environment therapeutic area group management assumption external datum significant asset research development available perform sensitivity analyse individual intangible asset impairment model assess level sensitivity key assumption focus work area assess management allowance risk addition assess reasonableness management assumption probability obtain regulatory approval comparison industry practice past history consideration group internal governance approval process information carry value product intangible asset available use pharmaceutical division refer following note significant accounting policy note general accounting principle key accounting judgement estimate assumption page note intangible assetsfinance report statutory auditor report roche group income tax uncertain tax position key audit matter response group operate wide range different tax audit procedure include obtain jurisdiction world tax treatment understand uncertain tax position inquiry tax filing subject challenge local tax authority employee tax department management respect crossborder transfer pricing arrangement affiliate inspect documentation relation tax good service finance transactionrelated tax exposure item include correspondence tax authority matter connection integration investment report issue tax advisor verify uncertain divestment license contract tax treatment involve tax position consider provide uncertainty include agreement transfer pricing necessary arrangement affiliate involve group global manufacturing supply chain significant item challenge assess management judgement eventual resolution probable tax authority accept uncertainty assistance local country treatment tax liability recognise financial tax specialist reperforme calculation statement reflect management well estimate estimate exposure take account statute outcome base fact know relevant limitation inspect thirdparty transfer pricing jurisdiction group open tax transfer pricing study evaluate applicable past experience matter tax authority range management interaction tax authority possible outcome broad december respective jurisdiction additionally tax group recognise current income tax liability specialist expertise assess appropriateness chf million include accrual uncertain key assumption management conclude tax position good estimate outcome focus area uncertainty audit approach include additional audit procedure estimate amount tax receivable payable consider uncertain tax position arise group require significant level expertise particular respect transfer pricing arrangement judgement good services transactionrelate tax matter information uncertain tax position refer follow note significant accounting policy note general accounting principle key accounting judgement estimate assumption page note income taxis roche group statutory auditor report finance report information board director responsible information information comprise information include finance report annual report include consolidated financial statement standalone financial statement company remuneration report auditor report thereon opinion consolidated financial statement cover information express form assurance conclusion thereon connection audit consolidated financial statement responsibility read information consider information materially inconsistent consolidated financial statement knowledge obtain audit appears materially misstate base work perform conclude material misstatement information require report fact report regard board director responsibilitie consolidated financial statement board director responsible preparation consolidate financial statement true fair view accordance ifrs provision swiss law internal control board director determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement board director responsible assess group ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate group cease operation realistic alternative auditor responsibility audit consolidated financial statement objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law isa sach detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement audit accordance swiss law isa sach exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance purpose express opinion effectiveness group internal control evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease continue go concern evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement represent underlie transaction event manner achieve fair presentationfinance report statutory auditor report roche group obtain sufficient appropriate audit evidence financial information entity business activity group express opinion consolidated financial statement responsible direction supervision performance group audit remain solely responsible audit opinion communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable action take eliminate threat safeguard apply matter communicate board director relevant committee determine matter significance audit consolidated financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co psch confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ag franois rouiller paul nichols license audit expert auditor charge basel january kpmg ag grosspeteranlage po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firm affiliate kpmg international limited private english company limit guarantee right reserve roche group multiyear overview supplementary information finance report multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply dividend propose board director retrospectivelyfinance report multiyear overview supplementary information roche group multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply dividend propose board director retrospectively roche group multiyear overview supplementary information finance report sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total finance report multiyear overview supplementary information roche group addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information finance report alternative performance measure financial information include financial review include certain alternative performance measure apm accounting measure define ifrs particular core result net work capital net operating asset free cash flow constant exchange rate apm instead consider alternative group consolidated financial result base ifrs apm comparable similarly title measure disclose company apm present financial review relate performance current year comparative period core result core result allow assessment group actual result define ifrs underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note exception commercial software intangible asset impairment goodwill note exclude acquisition accounting impact accounting merger acquisition alliance transaction financial review exclude discontinued operation currently exclude legal environmental case financial review exclude global issue outside healthcare sector group control exclude material treasury item major debt restructuring currently exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial reviewfinance report multiyear overview supplementary information roche group core result reconciliation millions chf intan intan pension normali global gible gible alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs ture sation ment action mental ment issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation millions chf intan intan pension normali global gible gible alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs ture sation ment action mental ment issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche group multiyear overview supplementary information finance report divisional core result reconciliation millions chf intan intan pension global gible gible alliance legal plan restruc amorti impair trans environ settle ifrs ture sation ment action mental ment core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation millions chf intan intan pension global gible gible alliance legal plan restruc amorti impair trans environ settle ifrs ture sation ment action mental ment core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operate profit finance report multiyear overview supplementary information roche group core ep basic core net income attributable roche shareholder chf million weight average number outstanding share nonvoting equity security calculate basic earning share million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number outstanding share nonvoting equity security calculate diluted earning share million core earning share diluted chf free cash flow free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business operate free cash flow calculate base ifrs operating profit adjust certain noncash item movement net work capital capital expenditure investment property plant equipment intangible asset principal portion lease liability pay lease asset operate free cash flow different cash flow operating activity define ias include capital expenditure responsibility divisional management exclude income taxis pay responsibility divisional management cash outflow define benefit plan allocate operate free cash flow base current service cost residual allocate treasury activity free cash flow calculate operate free cash flow adjust treasury activity taxis pay free cash flow different total cash flow define ia exclude dividend payment cash inflowsoutflow financing activity issuancerepayment debt purchasesale marketable security cash inflowsoutflow merger acquisition divestment operate free cash flow free cash flow calculate show table additional commentary adjustment item give financial review roche group multiyear overview supplementary information finance report operate free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia add income taxis pay deduct investment property plant equipment principal portion lease liability pay investment intangible asset disposal property plant equipment disposal intangible asset pension postemployment benefit add total payment define benefit plan deduct allocation payment operate free cash flow acquisitionrelate item include transaction cost operate item operate free cash flow free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia deduct investment property plant equipment principal portion lease liability pay investment intangible asset disposal property plant equipment disposal intangible asset interest pay operating item include acquisitionrelate item treasury item free cash flow finance report multiyear overview supplementary information roche group supplementary information calculate divisional operate free cash flow show table divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment ebitda group use earning interest tax depreciation amortisation ebitda internal management report external communication opinion group management operate free cash flow give useful consistent measurement cash earning ebitda include noncash item provision allowance trade receivables inventory certain noncash entry arise acquisition accounting pension accounting operate free cash flow include cash investment property plant equipment lease asset intangible asset ebitda exclude cost cash outflow item convenience reader use ebitda provide table start point use core result exclude amortisation impairment goodwill intangible asset ebitda core result million chf pharmaceutical diagnostic corporate group ebitda core operate profit depreciation impairment property plant equipment core basis depreciation impairment rightofuse asset core basis amortisation impairment commercial software intangible asset core basis ebitda margin sale roche group multiyear overview supplementary information finance report net operating asset net operating asset allow assessment group operate performance business independently finance tax activity net operating asset calculate property plant equipment lease asset rightofuse asset goodwill intangible asset net work capital longterm net operating asset minus provision calculation net operating asset disclose note annual financial statement show table net operating asset reconciliation millions chf treasury pharmaceutical diagnostic corporate taxation group property plant equipment rightofuse asset goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability lease liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset net operating asset reconciliation millions chf treasury pharmaceutical diagnostic corporate taxation group property plant equipment rightofuse asset goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability lease liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset finance report multiyear overview supplementary information roche group net debt net debt monitor group overall short longterm liquidity net debt calculate sum total longterm shortterm debt marketable security cash cash equivalent net debt calculation include detail movement current year show table financial review net work capital net working capital assess group efficiency utilise asset shortterm liquidity net trade work capital calculate trade receivables inventory minus trade payable net work capital calculate net trade work capital adjust receivables payable net work capital net trade work capital calculation show table pharmaceutical division diagnostic division corporate financial review constant exchange rate certain percentage change financial review calculate constant exchange rate cer allow assessment group financial performance effect exchange rate fluctuation eliminate percentage change constant exchange rate calculate simulation reconsolidate current report period prior period number constant currency exchange rate equal average exchange rate prior year example cer change line item equivalent calculate average exchange rate year end december line item line item subsequently calculate change percent respect recalculate number foreign exchange gain loss gain loss net monetary position hyperinflationary economy exclude calculation cer growth rate earning share disclosure country significant devaluation local currency current year simulation use average exchange rate current year instead prior year avoid cer growth rate artificially inflate roche group roche security finance report roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr standard poors index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july finance report roche security roche group number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total issue number share nonvoting equity security genussscheine hold total outstanding follow closing share repurchase transaction december number share nonvoting equity security genussscheine hold roche group december summarise table include bearer share cancel february detail find note roche group consolidate financial statement datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend c stock price share b open high low yearend stock price nonvoting equity security genussschein b open high low yearend nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director market capitalisation millions chf yearend roche group roche securities finance report key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine stock code share nonvoting equity security american depositary receipt adr swiss exchange ro rog bloomberg ro sw rog vx rhhby reuters ros rogvx rhhbypkfinance report roche holding ltd basel roche holding ltd basel financial statement note financial statement summary significant accounting policy significant shareholder shareholder equity fulltime equivalent employee contingent liability board executive shareholding appropriation available earning statutory auditor report general meeting roche holding ltd basel roche holding ltd basel financial statement finance report financial statement balance sheet millions chf december december current asset cash cash equivalent marketable security accounts receivable group company shortterm loan group company accrue dividend receivable subsidiary shortterm receivables total current asset noncurrent asset longterm loan group company investment total noncurrent asset total asset shortterm liability account payable group company interestbeare liability bank interestbeare liability group company shortterm liabilitie provision total shortterm liability longterm liability provision total longterm liability total liability shareholder equity share capital nonvoting equity security genussscheine p p legal retain earning general legal retain earning voluntary reserve retain earning free reserve special reserve available earning balance bring forward previous year net income year equity instrument total shareholder equity total shareholder equity liability pm pro memoria nonvoting equity security genussscheine nominal valuefinance report financial statement roche holding ltd basel income statement millions chf year end december income income investment dividend income financial income interest income loan group company income marketable security guarantee fee income group company income total income expense administration expense expense financial expense direct taxis total expense net income roche holding ltd basel note financial statement finance report note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel company prepare accordance provision swiss law accounting financial report nd title swiss code obligation co prescribe law significant accounting principle apply describe company prepare consolidated financial statement accordance recognise accounting standard international financial reporting standard accordance co company decide forgo present additional information audit fee note cash flow statement valuation method translation foreign currency marketable security report low cost market value financial asset include investment report cost appropriate writedown equity instrument recognise cost deduct equity time purchase equity instrument sell gain loss recognise income statement asset liability denominate foreign currency translate swiss franc yearend rate exchange investment translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer investment direct indirect investment company subsidiary list note roche group annual financial statement list exclude chugais subsidiary company material notably company inactive dormant liquidation ownership interest equal voting right equity instrument include treasury share equity instrument include treasury share recognise purchase price deduct shareholder equity time purchase case resale gain loss recognise financial income financial expense cancellation bearer share repurchase share derecognise corresponding decrease share capital nominal value cancel share voluntary reserve retain earning exceeding dividend distribution equity instrument hold company include treasury share income investment dividend income dividend income distribution subsidiary accrue financial statement company provide annual general meeting subsidiary approve distribution dividend prior approval annual financial statement roche holding ltd board director income investment include dividend income chf billion declare subsidiary business year approve annual general meeting january accrue december include accrue dividend receivable subsidiary tax direct taxis include corporate income capital taxesfinance report note financial statement roche holding ltd basel income income relate reversal allowance loan receivable previously record impairment investment income include chf million release hide reserve tax prior year expense expense mainly consist impairment investment dividend payment shareholder equity share repurchase share capital reduction november extraordinary general meeting company shareholder approve share capital reduction chf million chf million chf million cancellation share repurchase novartis december company repurchase bearer share nominal value chf hold novartis total consideration chf billion december repurchase share report treasury share repurchase price exclude transaction cost share cancel february necessary legal procedure complete cancellation share company share capital decrease chf million chf million chf million reduction share capital effective begin february entry share capital reduction commercial register canton basel stadt february publication share capital reduction swiss official gazette commerce february chf billion bridge loan facility draw december finance share repurchase fully repay december bridge loan facility outstanding chf billion share capital follow share capital reduction describe december share capital amount chf million share capital consist bearer share nominal value chf december bearer share include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate equity instrument include treasury share december company hold bearer share treasury share repurchase total consideration chf billion repurchase price exclude transaction cost deduct shareholder equity company purchase sell bearer share sales bearer share describe bearer share hold treasury share cancel february necessary legal procedure complete december company hold nonvoting equity security company purchase sell nonvoting equity security article b revise swiss code obligation co effective january require creation additional legal reserve equity instrument hold subsidiary company parent company roche group control include foundation include ifrs consolidation scope qualify subsidiary article b co effective december december foundation hold bearer share nonvoting equity security cost chf million accordance article b revise co company record legal reserve equity instrument chf million january include legal retain earning roche holding ltd basel note financial statement finance report movement recognise amount million chf voluntary reserve retain earning legal retain special available equity share capital earnings free reserve reserve earning instrument total equity january net income dividend transaction equity instrument december net income dividend transaction equity instrument share repurchase december net income dividend release free reserve special reserve share capital reduction transaction equity instrument december finance report note financial statement roche holding ltd basel contingent liability guarantee company issue guarantee certain bond note commercial paper note credit facility group company nominal outstanding december chf billion chf billion describe note roche group annual financial statement significant shareholder share company bearer share reason company register shareholder follow figure base information receive shareholder exercise voting right annual general meeting march information available company control shareholder december base information supply group shareholder group pool voting right own share represent issue share december share represent issue share exclude treasury share hold company cancel february voting power note figure include share pooled voting right hold outside group individual member group december shareholder group announce continue shareholder pool agreement modify shareholder composition group consist mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement exist duration pool extend indefinite period december base information supply group ms maja oeri member pool hold share independently pool represent issue share december share represent issue share exclude treasury share hold company cancel february voting power fulltime equivalent employee annual average number fulltime equivalent employee exceed people roche holding ltd basel note financial statement finance report board executive shareholding board director director mr andr hoffmann dr jrg duschmal certain member founder family closely associate belong shareholder group pool voting right end shareholder group hold share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine c franz hoffmann j brown na na p bulcke na na h clever na na j duschmal p frost hauser r p lifton e j mahmood na na b poussot schwan b c suessmuth dyckerhoff c c total include share hold shareholder group pool voting right b member corporate executive committee dr schwans shareholdings disclose table c jointly hold close relative close relative hauser hold nonvoting equity security genussscheine e prof dr r p lifton hold roche american depositary receipt adr adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july corporate executive committee end year member corporate executive committee person closely associate hold share nonvoting equity security genussscheine show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan b anderson hippe b schinecker c wilbur total equity compensation award ssar stocksettle stock appreciation right rsus restrict stock unit b close relative hippe hold nonvoting equity security genussscheine nonefinance report note financial statement roche holding ltd basel remuneration equity compensation plan member corporate executive committee compose stocksettle stock appreciation right ssar restrict stock unit rsus december members corporate executive committee hold stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information give remuneration report include annual report page ssar award grant member corporate executive committee vest year award grant vested year ssar award hold december year issue total schwan b anderson hippe schinecker c wilbur total strike price chf expiry date mar mar mar mar mar mar mar december members corporate executive committee hold restrict stock unit rsus show table term vest condition award disclose note roche group annual financial statement additional supplementary information give remuneration report include annual report page rsu award grant member corporate executive committee vest year nonvoting equity security andor share remain block year rsu award hold december year issue total schwan b anderson hippe schinecker c wilbur total information relate number value right option award grant employee roche group member board director corporate executive committee company disclose note note roche group annual financial statement roche holding ltd basel appropriation available earning finance report appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year transfer legal reserve equity instrument release free reserve release special reserve reduction resolution extraordinary general meeting november share cancel february necessary legal procedure complete total available earning appropriation available earning distribution ordinary dividend chf gross share entitle dividend nonvoting equity security genussschein chf year total appropriation available earning carry forward account article b revise swiss code obligation co effective january require creation additional legal reserve equity instrument hold subsidiary company parent company roche group control include foundation include ifrs consolidation scope qualify subsidiary article b co effective december finance report statutory auditor report roche holding ltd basel statutory auditor report general meeting roche holding ltd basel report audit financial statement opinion audit financial statement roche holding ltd company comprise balance sheet december income statement year end note financial statement include summary significant accounting policy opinion financial statement page comply swiss law company article incorporation basis opinion conduct audit accordance swiss law swiss standard audit sach responsibility provision standard describe auditor responsibility audit financial statement section report independent company accordance provision swiss law requirement swiss audit profession fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion key audit matter key audit matter matter professional judgement significance audit financial statement current period determine key audit matter communicate report information board director responsible information information comprise information include finance report annual report include consolidated financial statement standalone financial statement company compensation report auditor report thereon opinion financial statement cover information express form assurance conclusion thereon connection audit financial statement responsibility read information consider information materially inconsistent financial statement knowledge obtain audit appears materially misstate base work perform conclude material misstatement information require report fact report regard roche holding ltd basel statutory auditor report finance report board director responsibilitie financial statement board director responsible preparation financial statement accordance provision swiss law company article incorporation internal control board director determine necessary enable preparation financial statement free material misstatement fraud error prepare financial statement board director responsible assess company ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate company cease operation realistic alternative auditor responsibility audit financial statement objective obtain reasonable assurance financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law sach detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis financial statement audit accordance swiss law sach exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance purpose express opinion effectiveness company internal control evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt company ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause company cease continue go concern communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable action take eliminate threat safeguard apply matter communicate board director relevant committee determine matter significance audit financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communicationfinance report statutory auditor report roche holding ltd basel report legal regulatory requirement accordance article para item co psch confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ag franois rouiller paul nichols license audit expert auditor charge basel january kpmg ag grosspeteranlage po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firm affiliate kpmg international limited private english company limited guarantee right reservedpublishe cautionary statement forwardlooke statement f hoffmannla roche ltd finance report contain certain forwardlooking statement group communication forwardlooke statement identify word basel switzerland believe expect anticipate project intend tel seek estimate future similar expression wwwrochecom discussion thing strategy goal plan intention factor cause actual result differ orderdownload publication materially future reflect forwardlooke internet rochecompublication statement contain annual report email materialsmanagementmmrochecom pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring media relation product market fluctuation currency exchange rate tel general financial market condition uncertaintie email mediarelationsrochecom discovery development marketing new product new use exist product include limitation negative result investor relation clinical trial research project unexpected effect tel pipeline market product increase government pricing email investorrelationsrochecom pressure interruption production loss inability obtain adequate protection intellectual property right corporate sustainability committee litigation loss key executive employee tel adverse publicity news coverage email corporatesustainabilityrochecom statement earning share growth profit annual general meeting forecast interpret mean roche march earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark legally protect link thirdparty page provide convenience express opinion content thirdparty page expressly disclaim liability thirdparty information use roche finance report publish german english case doubt difference interpretation english version shall prevail german text reporting consist actual annual report finance report contain annual financial statement consolidated financial statement regard content management report article incorporation consist aforementioned report exception remuneration report print nonchlorine bleach fsccertifie paperf hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom